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1.0 INTRODUCTION  
1.1 Inflammatory bowel disease (IBD)  
Inflammatory bowel disease (IBD) is a global healthcare problem with a sustained increasing 
incidence (Ko et al., 2014) (Figure 1). Accumulating evidence suggests that IBD results from 
an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host. 
Although the etiology of IBD remains largely unknown, recent research indicated that the 
individual genetic susceptibility, intestinal microbial flora and immune responses are all 
involved and functionally integrated in the pathogenesis of IBD (Danese and Fiocchi, 2006; 
Podolsky, 2002). It is of interest that in several countries with historically low rates of IBD, a 
pattern of rising incidence in the past one to two decades, particularly for Crohn’s disease 
(CD), has occurred, suggesting that environmental factors are also involved (Ko et al., 2014). 
The idiopathic inflammatory bowel diseases comprise two types of chronic intestinal disorders: 
Crohn’s disease (CD) and ulcerative colitis (UC) which are distinct chronic bowel-relapsing 
inflammatory disorders. CD can cause transmural inflammation and affect any part of the 
gastrointestinal tract (most commonly, the terminal ileum or the perianal region) in a non-
continuous type. Unlike UC, CD is commonly associated with complications such as abscesses, 
fistulas and strictures. In contrast, UC is typified by mucosal inflammation and limited to the 
colon (Abraham and Cho, 2009). While CD and UC involve different genetic vulnerabilities, 
pathological abnormalities, and different regions of involvement in the intestinal tract, both are 
characterized by gastrointestinal symptoms such as bloody diarrhea, weight loss, and 
abdominal pain, as well as extra-intestinal manifestations such as joint pain, uveitis, and 
erythema nodosum. Their etiologies are unknown, but they are characterized by an imbalanced 
production of pro-inflammatory mediators, e.g., tumor necrosis factor (TNF)-α, as well as 
increased recruitment of leukocytes to the site of inflammation. Advantages in understanding 
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the role of the inflammatory pathways in IBD and an inadequate response to conventional 
therapy in a large portion of patients, has over the last two decades lead to new therapies which 
includes, for example, the TNF-α inhibitors, designed to target and neutralize the effect of 
TNF-α. However, convenient alternative therapeutics targeting other immune pathways are 
needed not only for patients with IBD refractory to conventional therapy, that traditionally 
includes steroids and 5-ASA treatments (Sewell et al., 2010; Jones et al., 2011) but even 
because, although these drugs may be effective, their long-term use can induce severe side 
effects that have detrimental impact on life quality of patients (Blonski et al., 2011). For this 
purpose, experimental models have proven to be important tools for detecting potential 
therapeutic agents and for investigating the mechanisms of IBD pathogenesis.  
In the present work, the experimental model of colitis induced  by  dinitrobenzenesulfonic acid 
(DNBS) has been used (Hibi et al., 2002). Granulomas with infiltration of inflammatory cells 
in all layers were seen in the intestine of this model. The isolated macrophages produced large 
amounts of interleukin-12 (IL-12), and the lymphocytes produced large amounts of interferon-γ 
(IFN-γ) and interleukin-2 (IL-2). This evidence suggests that the colitis seen in this model was 
induced by a Th type-1 response (Neurath et al., 1995). It has been noted that water absorption 
in the inflamed mucosa is markedly diminished in this model and this effect would be expected 
to contribute to the diarrhea that occurs not only in this animal model but also in human IBD. 
The DNBS model serves in clinical investigations for the development and testing of new 
therapeutic molecules that have the potential to enter into the clinic. 
Finally, it is noteworthy that there is a link connection between IBD and colorectal cancer 
(CRC),  highlighted by the observation that patients with IBD has an increased risk for CRC 
(Burisch and Munkholm, 2013). The risk is related to the duration and the anatomic extent of 
the disease (Ekbom et al., 1990). 
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Figure 1.  Epidemiology and Natural History of Inflammatory Bowel Diseases (IBD): the 
global map of IBD: red refers to annual incidence greater than 10/105, orange to incidence of 
5–10/105, green to incidence less than 4/105, yellow to low incidence that is continuously 
increasing. Absence of color indicates absence of data (From: Cosnes et at., Gastroenterolgy 
2011;140:1785-1794). 
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1.2 Colorectal cancer (CRC) 
Colorectal cancer (CRC) is an important health problem across the world. In Europe each year 
approximately 435,000 people are newly diagnosed with CRC (Ferlay et al., 2008); about half 
of these patients die of the disease making CRC the second leading cause of cancer deaths in 
Europe. Similarly, in 2014, an estimated 136,830 new cases of CRC were diagnosed in the 
USA, with 50,310 estimated deaths (Siegel at al., 2014) (Figure 2). CRC is thought to arise as 
the result of a series of histopathologic and molecular changes that transform normal colonic 
epithelial cells into a colorectal carcinoma, with aberrant crypt foci (ACF) and polyps as 
intermediate steps in this process (Markowitz and Bertagnolli, 2009). This multi-step process 
spans 10 to 15 years, thereby providing an opportunity for prevention (Half and Arber, 2009). 
Surgery is the cornerstone for cure in localized colorectal cancer (Sargent et al., 2007). 
Chemotherapy after surgery (adjuvant chemotherapy, in high risk stage II and stage III CRC 
patients) vs surgery alone reduced the risk of cancer relapse (Cunningham et al., 2010; Wolpin 
and Meyer, 2008). Drugs used in colorectal cancer chemotherapy include fluorouracil, 
irinotecan, oxaliplatin, angiogenesis inhibitors (i.e. bevacizumab) and epidermal growth factor 
receptor inhibitors (i.e. cetuximab and and panitumumab) (Wolpin and Meyer, 2008). Despite 
many progresses, and improvement of overall survival to nearly 2 years for non-resectable 
disease, cures for this kind of neoplasia remain unsatisfactory (Cunningham et al., 2010). Also, 
the new chemotherapeutic agents (i.e. the biologicals cetuximab, panitumumab and 
bevacizumab) have not come without a significant cost to the health care system (Wolpin and 
Meyer, 2008).  
In the present work we used to different models of colon cancer, i.e  the azoxymethane (AOM) 
model, which is particularly appropriate for testing compounds with putative chemopreventive 
action and the xenograft model, which is used to verify possible curative (therapeutic) effects. 
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The AOM colon cancer model is extensively used in the study of the underlying mechanisms of 
human sporadic colon cancer. AOM is a potent carcinogen causing a high incidence of colon 
cancer in rodents. Development of this cancer closely mirrors the pattern seen in humans. 
Repetitive intra-peritoneal treatment of rodents with AOM causes tumours specifically in the 
distal colon. Following AOM treatment, the epithelial cells undergo pathogenesis from minor 
lesion ACF, to adenoma and malignant adenocarcinoma. The in vivo metabolite of AOM 
causes DNA mutations, changing the nucleotides from G:C to A:T. The duration of AOM-
induced colon cancer takes 14 weeks in mice or rats (Takahashi and Wakabayashi, 2004).  In 
the xenograft model,  human tumor cells are implanted  into recipient mice. To prevent 
xenograft rejection, nude mice are used, in which the nu gene is knocked out, resulting in 
hairless thymus-less mice which cannot generate T lymphocytes. The accessibility of these 
subcutaneous tumors is tremendous advantageous for monitoring tumor progression and for 
assessing the effects of therapeutic intervention (Voskoglou-Nomikos et al., 2003). 
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Figure 2. Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths by Sex, 
United States, 2014 (From: Siegel et at., CA Cancer J Clin. 2014;64:9-29) 
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1.3 Cannabis sativa  
Cannabis sativa (Family: Cannabaceae) is an annual plant, that gets erect stems growing from 
1 to 3 m or more high, very slightly branched, having greyish-green hairs. The leaves are 
palmate, with five to seven leaflets (three on the upper leaves), numerous, on long thin petioles 
with acute stipules at the base, linear-lanceolate, tapering at both ends, the margins sharply 
serrate, smooth and dark green on the upper surface, lighter and downy on the under one. The 
small flowers are unisexual, the male having five almost separate, downy, pale yellowish 
segments, and the female a single, hairy, glandular, five-veined leaf enclosing the ovary in a 
sheath. The ovary is smooth, one-celled, with one hanging ovule and two long, hairy thread-
like stigmas extending beyond the flower for more than its own length. The fruit is small, 
smooth, light brownish-grey in colour, and completely filled by the seed (Quimby, 1974) 
(Figure 3). Cannabis has a long history of use both as a medicine and as a recreational drug, the 
written records of its use span more than five millennia. During the last century Cannabis 
moved from being a frequently prescribed item for a variety of therapeutic conditions, through 
a period of increasing opposition to its use because of its potential for abuse, to the point where 
its use was completely withdrawn in the mid-twentieth century. Recently, there has been a 
resurgence of interest in Cannabis as a medicine for the treatment of conditions unresponsive to 
other types of therapy. In the last 20 years an increasing number of patients with severely 
debilitating diseases such as multiple sclerosis have used it to obtain relief.  
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Figure 3. Cannabis sativa, leaves 
 
 
 
 
 
 
 
9 
 
1.4 Phytocannabinoids 
The limitation of the therapeutic utility of Cannabis is its assigned psychoactive effects. 
Cannabis sativa produces over 421 chemical compounds, including about 100 terpeno-phenol 
compounds named phytocannabinoids (pCBs) that have not been detected in any other plant. 
pCBs are lipid-soluble chemicals present in the resin secreted from trichomes that are 
abundantly produced by female plants of the Cannabis sativa herb (Hill et al., 2012). The plant 
can be genetically manipulated to alter the relative ratios of the pCBs produced and this 
approach has been successfully used to develop a legitimate medicinal product. Thus, it is 
possible to use solely horticultural techniques to produce cloned plants which are uniformly 
enriched in different, specific pCB and/or to transform a raw material into a botanical drug 
substance as an active pharmaceutical ingredient, which can then be formulated into a botanical 
drug product (de Meijer et al., 2003).  
Historically, among the phytocannabinoids, most attention has been paid to ∆9-
tetrahydrocannabinol (∆9-THC), which is the most psychotropic component and binds specific 
G protein-coupled receptors named cannabinoid (CB1 and CB2) receptors. The discovery of a 
specific cell membrane receptor for ∆9-THC was followed by isolation and identification of 
endogenous (animal) ligands termed endocannabinoids. The two main endocannabinoids are 
anandamide [which is metabolized mostly by fatty acid amide hydrolase (FAAH)] and 2-
arachidonoylglycerol (2-AG which is mostly degraded by monoglyceride lipase (MAGL)]. 
Cannabinoid receptors, endogenous ligands that activate them, and the mechanisms for 
endocannabinoid biosynthesis and inactivation constitute the ‘‘endocannabinoid system’’. With 
its ability to modulate several physiological and pathophysiological processes the 
endocannabinoid system represents a potential target for pharmacotherapy (Di Marzo, 2008).  
In addition to pharmacological modulation of the endocannabinoid system, a different approach 
to minimize the well-known psychotropic side effects of Cannabis is the use of pCBs with very 
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weak or no psychotropic effects. These include cannabidiol (CBD), cannabigerol (CBG), 
cannabichromene (CBC), ∆9-tetrahydrocannabivarin (∆9-THCV), cannabidivarin (CBDV) as 
well as cannabinoid acids such as ∆9-tetrahydrocannabinolic acid (∆9-THCA) and cannabidiolic 
acid (CBDA) (Figure 4). These compounds exert multiple actions through mechanisms which 
are only partially related to modulation of the endocannabinoid system (Izzo et al., 2009).  
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Figure 4. Chemical structures of the principals phytocannabinoids 
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1.4.1 Targets involved in the pharmacological action of phytocannabinoids 
The main targets involved in the pCBs actions include: 
The endogenous cannabinoid system: The endogenous cannabinoid system include two Gi/o 
coupled membrane receptors, named CB1 and CB2 receptors, the endogenous ligands that 
activate them  (i.e. the endocannabinoids, anandamide and 2-AG) and the proteins involved in 
endocannabinoid synthesis and inactivation. Endocannabinoids are biosynthesized ‘on demand’ 
from membrane phospholipids by the action of a number of enzymes including N-acyl-
phosphatidylethanolamine selective phospholipase D (NAPE-PLD, involved in anandamide 
biosynthesis) and diacylglycerol lipase (DAGL, involved in 2-AG biosynthesis), and are 
inactivated through a reuptake process (facilitated by a putative endocannabinoid membrane 
transporter), followed by enzymatic degradation catalysed by the fatty acid amide hydrolase 
(FAAH, in the case of anandamide and, to some extent, 2-AG) or monoacylglycerol lipase 
(MAGL, in the case of 2-AG) (Di Marzo, 2008). 
Transient receptor potential (TRP) channels:  
Transient receptor potential (TRP) channels form a large superfamily of ion channels that are 
important in several pathophysiological processes, which include (but are not limited to) pain, 
inflammation, airways hypersensitivity, cardiac hypertrophy and cell death. TRP channels have 
been subdivided into seven subgroups according to their sequence homology: TRP canonical 
(TRPC), TRP vanilloid (TRPV), TRP melastatin (TRPM), TRP mucolipin (TRPML1), TRP 
polycystin (TRPP), TRP ankyrin (TRPA) and TRP NompC-like (TRPN) transmembrane 
proteins (Kaneko and Szallasi, 2013) 
Adenosine uptake: Uptake of adenosine is a primary mechanism of terminating adenosine 
signalling. Adenosine is a multifunctional, ubiquitous molecule that activate four known 
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adenosine receptors (A1, A2A, A2B and A3). Adenosine A2A receptor is an important 
regulator of inflammation (Izzo et al., 2009). 
G protein-coupled receptor 55 (GPR55): GPR55 is an orphan G-protein-coupled receptor 
originally identified in silico from the expressed sequence tags database. GPR55 may be 
activated by plant and synthetic endocannabinoids as well as by anandamide-related 
acylethanolamides and may be antagonized by cannabidiol (Izzo et al., 2009).  
Peroxisome proliferator-activated receptors (PPARs): Peroxisome proliferators- activated 
receptors (PPARs) belong to a family of nuclear receptors comprising three isoforms: α, β and 
γ. Among these, PPARγ is involved in the regulation of cellular glucose uptake, protection 
against atherosclerosis and control of immune reactions. Activation of PPARγ attenuates 
neurodegenerative and inflammatory processes (Izzo et al., 2009). 
5-hydroxytryptamine subtype 1A receptor (5-HT1A): The 5-HT1A receptor is one of the best-
characterized 5-HT receptors. This G protein-coupled receptor is involved a number of 
physiological or pathophysiological processes, including anxiety, mood, depression, 
vasoreactive headache, food intake, immune regulation, and cardiovascular regulation (Izzo et 
al., 2009). 
The pCBs investigated in the present work are: cannabidiol (CBD), a Cannabis extract with 
high content in CBD (named CBD BDS, i.e. CBD botanical drug substance), cannabigerol 
(CBG), cannabichromene (CBC) and ∆9-tetrahydrocannabivarin (THCV).  
1.4.2 Cannabigerol (CBG) 
CBG is a non-psychotropic cannabinoid obtained in 1964 by Gaoni and Mechoulam when they 
separated a hexane extract of hashish on Florisil (Izzo et al., 2009). CBG appears as a relatively 
low concentration intermediate in the plant, although recent breeding works have yielded 
Cannabis chemotypes  expressing 100% of their phytocannabinoid content as CBG (de Meijer 
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and Hammond, 2005; de Meijer et al., 2009). Older and recent studies support analgesic, anti-
erythemic, antibacterial, antidepressant and antihyptertensive actions for this phytocannabinoid 
(Evans, 1991; Russo, 2011). Relevant for the present work, CBG has been proved to be 
cytotoxic in high dosage on human epithelioid carcinoma cells (Baek et al., 1998), to be 
effective against breast cancer (Ligresti et al., 2006) and to inhibit keratinocyte proliferation 
(Wilkinson and Williamson, 2007). Pharmacodynamic studies have shown that CBG interacts 
with receptors/enzymes involved both in inflammation and in carcinogenesis. Specifically, 
CBG is a weak partial agonist of CB1 and CB2 receptors (Cascio et al., 2010), inhibits the 
reuptake of endocannabinoids (De Petrocellis et al., 2011), is a  potent 5-HT1A antagonist 
(Cascio et al., 2010) and may interact with TRP channels. Among the TRP channels, CBG has 
been shown to be a TRPA1,  TRPV1 and TRPV2 agonist and, importantly, a potent TRPM8 
antagonist (De Petrocellis et al., 2011). 
1.4.3 Cannabichromene (CBC) 
The discovery of CBC, a non-psychotropic cannabinoid, was independently reported by 
Claussen and coworkers, and Gaoni and Mechoulam in 1966 (Izzo et al., 2009). CBC is one of 
four major cannabinoids in Cannabis sativa and it is known to be abundant in high-grade drug-
type marijuana, with little or no CBD (Holley et al., 1975). CBC represents 0.3% of the 
constituents from confiscated Cannabis preparations in the USA (Mehmedic et al., 2010). 
Despite the relative abundance of this phytocannabinoid, its pharmacological activity has been 
hardly at all investigated. Of relevance to the topic of the present study, CBC was shown to 
reduce carrageenan- and lipopolysaccharide (LPS)-induced paw oedema in rodents (Wirth et 
al., 1980; Turner and Elsohly, 1981; DeLong et al., 2010). Pharmacodynamic studies have 
shown that CBC is an inhibitor of endocannabinoid cellular reuptake (Ligresti et al., 2006), a 
weak inhibitor of MAGL (i.e. the main enzyme involved in the inactivation of the 
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endocannabinoid 2-AG) and a potent activator of transient receptor potential (TRP) ankyrin 1-
type (TRPA1) channels (De Petrocellis et al., 2008; De Petrocellis et al., 2012). Both 
endocannabinoids and TRPA1 are known to be involved in inflammatory processes (Burstein 
and Zurier, 2009; McMahon and Wood, 2006). 
1.4.4 ∆9-Tetrahydrocannabivarin (THCV) 
∆
9
-THCV, the n-propyl analogue of ∆9-THC, was detected in 1970 by Edward Gil and 
colleagues from a tincture of Cannabis BPC (then a licensed medicine in the UK). It is 
particularly abundant in Pakistani hashish. ∆9-THCV at low doses (<3 mg/kg) antagonizes ∆9-
THC effects and it shares the ability of synthetic CB1 antagonists to reduce food intake in mice 
(Izzo et al., 2009). THCV also behaves as CB2 partial agonist and via this mechanism exerts 
anti-inflammatory actions (Bolognini et al., 2010). 
1.4.5 Cannabidiol (CBD)     
CBD, a major non-psycotropic cannabinoid, was first isolated in 1940 by Adams and co-
workers, but its structure and stereochemistry were determined in 1963 by Mechoulam and 
Shvo. CBD is the most common phytocannabinoid in fibre (hemp) plants. 
CBD has an extremely safe profile in humans and exerts a number of pharmacological actions 
(e.g. analgesic/anti-inflammatory, antioxidant, neuroprotective) of potential clinical interest 
(Izzo et al., 2009). Few studies have investigated the effect of CBD in the gut. Specifically, 
CBD has been shown to reduce intestinal contractility (Capasso et al., 2008; Cluny et al., 2011) 
and to exert anti-inflammatory effects (Borrelli et al., 2009; Jamontt et al., 2010). In addition, 
CBD may inhibit FAAH (De Petrocellis et al., 2011) and exerts antioxidant action in colorectal 
carcinoma cell lines (Borrelli et al., 2009). Both FAAH inhibition (Izzo et al., 2008; Izzo and 
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Sharkey, 2010) and antioxidant effects (Klauning et al., 2011)  are potentially beneficial for gut 
diseases. 
1.4.6 Cannabis-extract with high content in cannabidiol (CBD BDS) 
Recent progress in plant biotechnology has made possible the cultivation of Cannabis 
chemotypes rich in specific pCBs, from which standardized extracts, containing known 
amounts of pCBs, may be obtained (Russo, 2011). The best studied among these extracts is 
generally referred as CBD botanical drug substance (CBD BDS, that is a standardized 
Cannabis extract with high content of CBD). CBD BDS is a main ingredient of a Cannabis-
derived medicine (sold under the brand name Sativex) used for the treatment of pain and 
spasticity associated with multiple sclerosis. Sativex is composed primarily of a 1:1 ratio of 
two Cannabis sativa extracts, CBD BDS and a Cannabis sativa extract with high content of ∆9-
THC (THC BDS). It is noteworthy that actually Sativex holds a III trials programme in cancer 
pain, beyond its approval for multiple sclerosis spasticity.  In several pharmacological assays, 
CBD BDS has been shown to be more potent or efficacious than pure CBD (Comelli et al., 
2008; Capasso et al., 2011; Russo, 2011; De Petrocellis et al., 2013), suggesting that additive 
or synergistic interactions can occur between CBD and minor pCBs (or the non-cannabinoid 
fraction) contained in the extract. This observation might be useful from a therapeutic 
viewpoint.  
1.5 Cannabinoids and intestinal inflammation 
Anecdotal reports suggesting a favourable impact of  Cannabis use in IBD patients. Such 
reports have recently encountered scientific evidence in a number of  published clinical trials in 
which the effect of Cannabis or THC has been evaluated in IBD patients (Lal et al., 2011; 
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Naftali et al., 2011; Lahat et al., 2012; Naftali et al. 2013). In Israel, inhaled Cannabis has been 
legally registered for palliative treatment of both CD and UC. 
Several studies investigating the effects of cannabinoids in rodent models of intestinal 
inflammation have identified a potential therapeutic role for these compounds in the treatment 
of IBD (for review see Wright et al., 2008; Izzo and Camilleri, 2009; Alhouayek and Muccioli, 
2012).  Protective actions have been described for non-selective CB1 and CB2 selective receptor 
agonists, FAAH or MAGL inhibitors (Izzo and Sharkey, 2010). Furthermore, 
endocannabinoids regulates intestinal barrier function in vivo through CB1 receptor activation 
(Zoppi et al., 2012). Conversely, experimental inflammation is aggravated in mice genetically 
lacking  CB1 or CB2 receptors or in mice treated with selective CB1 or CB2 receptor antagonists 
(Massa et al., 2004; Engel et al., 2010).  
pCBs have been also investigated in experimental models of intestinal inflammation, both in 
vitro and in vivo. THC and CBD have been shown to be protective in experimental models of 
colitis (Borrelli et al., 2009; Jamontt et al., 2010; Schicho and Storr, 2012). Additionally, THC 
inhibited the expression of TNF-α-induced interleukin-release from the human colonic 
epithelial cells  (Ihenetu et al., 2003) and  accelerated the recovery from EDTA- or cytokine-
induced increased permeability in intestinal epithelial cells (Alhamoruni et al., 2010; 
Alhamoruni et al., 2012). Finally, CBD has been shown to exert anti-inflammatory effects in 
human colonic cultures derived from ulcerative colitis patients (De Filippis et al., 2011). 
1.6 Cannabinoids and colon cancer  
In addition to their palliative effects on some cancer-associated symptoms, it is now well-
established that cannabinoids exert direct antitumoural actions via  CB receptor and non-CB 
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receptor mediated pathways in a broad spectrum of cancer types both in vitro and in vivo 
(Guzman, 2003; Hermanson and Marnett, 2011). 
Concerning colon cancer, it has been demonstrated that cannabinoids exert antiproliferative, 
antimetastatic and pro-apoptotic actions in colorectal carcinoma epithelial cells (Ligresti et al., 
2003; Greenhough et al., 2007; Cianchi et al., 2008; Wang et al., 2008; Sreevalsan et al., 2011) 
as well as antitumoural effects in experimental models of colon cancer (Izzo et al., 2008; 
Cianchi et al., 2008; Wang et al., 2008). The antitumour actions of cannabinoids may be 
mediated by activation of CB1, CB2 or by non-cannabinoid-mediated mechanisms. The 
mechanism of CB1 receptor-mediated apoptotic effects involves: i) inhibition of RAS–MAPK 
and PI3K–AKT pathways (Greenhough et al., 2007); ii) down-regulation of the anti-apoptotic 
factor survivin, mediated by a cyclic AMP-dependent protein kinase A signalling pathway 
(Wang et al., 2008); iii) stimulation of the de novo synthesis of the pro-apoptotic lipid mediator 
ceramide. The mechanism of CB2-receptor-mediated antitumour action involves ceramide 
production, with TNF-α acting as a link between cannabinoid receptor activation and ceramide 
biosynthesis (Izzo and Camilleri, 2009). In vivo, cannabinoid receptor agonists – or inhibitors 
of endocannabinoids inactivation - have been shown to exert protective effects against colon 
carcinogenesis induced by the carcinogenic substance azoxymethane, by xenografts in nude 
mice as well as in Apc mice (Izzo et al., 2008; Cianchi et al., 2008; Wang et al., 2008). Results 
suggest that cannabinoids might be protective at different stages of colon cancer progression 
either directly, through activation of CB1 or CB2 receptors, or indirectly, through elevation of 
endocannabinoid levels. 
Ligresti and colleagues have specifically demonstrated that THC and other non-psychotropic 
phytocannabinoid  reduced colorectal cancer (Caco-2) cells growth (Ligresti et al., 2006). In a 
more complete study, THC was shown to induce apoptosis in a number of colorectal  cancer 
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cell lines. The mechanism of cell death was believed to involve survival signalling pathways 
that are frequently deregulated in colorectal tumours, i.e. BAD activation via CB1-dependent 
RAS-MAPK and PI3K-AKT pathway inhibition (Greenhough  et al., 2007). However, there is 
a paucity of data on the effect of phytocannabinoids in experimental model of colon cancer in 
vivo. Recently, cannabinoids with little or  non-psychotropic action have been shown to exert 
beneficial effects in colon carcinogenesis. Specifically, i) the atypical cannabinoid O-1602 was 
shown to reduced tumour area and tumour incidence in colitis-associated colon cancer (Kargl et 
al., 2013); ii) LYR-8, a  hexahydrocannabinol analog, exerted anti-tumor effects in human 
colorectal xenografted tumours (Thapa et al., 2012). 
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2.0 AIM 
The aim of the present work has been to evaluate the effect and the mode of action of a number 
of Cannabis-derived non-psychotropic cannabinoids in experimental models of intestinal 
inflammation and colon cancer. These compounds include CBD, CBG, CBC and THCV. 
Additionally, a standardized Cannabis extract with high content of CBD (derived from a 
Cannabis chemotype rich in CBD) has been investigated. In order to unravel the potential anti-
inflammatory and antitumoural actions of pCBs in the gut, the DNBS model of colitis, the 
AOM model of colon cancer and the experimental tumours generated by xenograft injection of 
colorectal cancer cells have been used. The possible mode of action of the pCBs has been 
evaluated in isolated peritoneal macrophages (to investigate the anti-inflammatory effect) and 
in colorectal cancer cells (to assess possible antiproliferative,  apoptotic and genoprotective 
actions).  
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3.0 MATERIALS AND METHODS 
3.1 Drugs and reagents  
Cannabichromene (CBC), [purity by high-performance liquid chromatography (HPLC): 
96.3%]; cannabidiol (CBD) [purity by HPLC: 99.76%]; Cannabis sativa extract with a 65.6% 
w/w of CBD content [here named CBD botanical drug substance (CBD BDS), (see HPLC 
chromatogram in Figure 5 and composition in Table 1) was prepared as described below (see 
subheading “plant Material and extraction”); cannabidivarin (CBDV), (purity by HPLC; 95.0 
%); cannabigerol (CBG) [purity by HPLC: 99.0 %];  tetrahydrocannabivarin (THCV) [purity 
by HPLC: 95.0%] were kindly supplied by GW Pharmaceuticals (Porton Down, Wiltshire, 
UK). The concentrations (or doses) of CBD BDS reported in the present thesis indicated the 
amount of CBD contained in the extract (e.g., 1 µmol of CBD BDS contained 1 µmol of CBD). 
Rimonabant and SR144528 were supplied by SANOFI Recherche, (Montpellier, France).  
ACEA, AMTB, AM251, AM630, capsazepine and JWH133 were purchased from Tocris 
(Bristol, UK).  
Azoxymethane (AOM), cadmium, 2,3-iaminonaphtalene (DAN), 2′,7′-dichlorofluorescin 
diacetate (DCFH-DA), dinitrobenzene sulphonic acid (DNBS), fluorescein isothiocyanate 
(FITC)-conjugated dextran (molecular mass 3-5 kDa), hydrogen peroxide (H2O2), 
lipopolysaccharide (LPS, from Escherichia coli serotype O111:B4), myeloperoxidase (MPO) 
from human leucocytes, 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
neutral red solution, ruthenium red, spermine, thioglycollate medium  were purchase from 
Sigma (Milan, Italy). 
MatrigelTM was obtained from BD Biosciences (Buccinasco, Milan, Italy). 
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All reagents for cell culture and western blot analysis were obtained from Sigma Aldrich S.r.l. 
(Milan, Italy), Amersham Biosciences Inc. (UK), Bio-Rad Laboratories (USA) and Microtech 
S.r.l. (Naples, Italy).  Methyl-[3H]-thymidine was purchased from PerkinElmer (Monza, Italy). 
For radioligand binding experiments, [35S]GTPγS (1250 Ci/mmol) and  [3H]CP55940 (160 
Ci/mmol) were obtained from PerkinElmer Life Sciences (Boston, MA), GTPγS from Roche 
Diagnostic (Indianapolis, IN), GDP from Sigma-Aldrich (UK).  
The vehicle used for drugs dissolving for in vivo experiments was constituted by 10% (v/v) 
ethanol, 10% (v/v) Tween-20, 80% (v/v) saline, [2 ml/kg, intraperitoneally (ip); DNBS was 
dissolved in 50% ethanol (0.15 ml/mouse, intrarectally). 
All the drugs used for in vitro experiments were dissolved in DMSO (0.01% DMSO v/v in cell 
media) and in the radioligand binding assays with hCB1/hCB2 CHO cells (0.1% DMSO v/v) 
had no effect on measured response.  
Only CBC was dissolved in ethanol (for in vitro experiments), in DMSO (for radioligand 
assays) and its vehicles (0.01% ethanol in vitro; 0.1% DMSO for radioligand assays)  had no 
significant effects on the responses under study. 
Plant material and extraction 
A Cannabis sativa chemotype cloned to have a controlled high amount of CBD was used (de 
Meijer et al., 2003). Cannabis sativa was grown in highly secure computer-controlled 
glasshouses. All aspects of the growing climate, including temperature, air change and 
photoperiod, were computer-controlled and the plants were grown without the use of pesticides 
(see details at http://www.gwpharma.com). Cannabis dry  flowers and leaves were extracted at 
room temperature with CO2 to give an extract which, evaporated to dryness, was a brownish 
solid. A portion of the extract was dissolved in methanol for HPLC analysis (Agilent 1100) 
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using a C18 column (150 x 4.6 mm, 1 ml/min flow rate). HPLC chromatogram and 
composition of the main cannabinoids are reported in Figure 5 and Table 1, respectively. 
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Figure 5. HPLC chromatogram of Cannabis sativa CO2 extract. Retention time for cannabidiol 
(CBD) and the other phytocannabinoids [cannabidivarin (CBDV), cannabidiolic acid (CBDA), 
cannabinol (CBN), ∆9-tetrahydrocannabinol (THC) and cannabichromene (CBC)] are 
indicated. 
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Table 1. Content of the main phytocannabinoids contained in Cannabis-extract with high 
content in cannabidiol (CBD BDS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHYTOCANNABINOID CONTENT 
(% w/w) 
Cannabidiol (CBD) 65.9 
∆
9
-tetrahydrocannabinol 2.4% 
Cannabigerol 1.0% 
Cannabidivarin 0.9% 
Cannabidiolic acid 0.3% 
Cannabinol 0.1% 
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3.2 In vivo studies 
3.2.1 Animals 
For colorectal cancer azoxymethane (AOM) model, for dinitrobenzene sulphonic acid (DNBS)-
induced colitis model and thioglycollate-elicitation mouse peritoneal macrophages 
experiments, male ICR mice, weighing 28–32 g, were used after 1-week acclimation period 
(temperature 23±2°C and humidity 60%). Mice were fed ad libitum with standard food, except 
for the 24-h period immediately preceding the administration of DNBS.  
For colorectal cancer xenograft model athymic female mice were used, fed ad libitum with 
sterile mouse food and maintained under pathogen-free conditions. All the animals used were 
purchased from Harlan Laboratories (S. Pietro al Natisone, Italy). 
All animal procedures were in conformity with the principles of laboratory animal care (NIH 
publication no.86–23, revised 1985) and the Italian D.L. no.116 of January 27, 1992 and 
associated guidelines in the European Communities Council Directive of November 24, 1986 
(86/609/ECC).  
3.2.2 Colorectal cancer azoxymethane (AOM) model 
AOM (40 mg/kg in total, ip) was administered, at the single dose of 10 mg/kg, at the beginning 
of the  first, second, third and fourth week. The phytocannabinoids (CBD 1 and 5 mg/kg, CBD 
BDS 5 mg/kg and CBG 1 and 5 mg/kg) were given (ip) three times a week starting one week 
before the first administration of AOM. All animals were euthanized by asphyxiation with CO2 
three months after the first injection of AOM. Based on our laboratory experience, this time (at 
the dose of AOM used) was associated with the occurrence of a significant number of aberrant 
crypt foci (ACF, which are considered pre-neoplastic lesions), polyps and tumours (Izzo et al., 
2008). 
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For ACF, polyps and tumours determination, the colons were rapidly removed after sacrifice, 
washed with saline, opened longitudinally, laid flat on a polystyrene board and fixed with 10% 
buffered formaldehyde solution before staining with 0.2% methylene blue in saline. Colons 
were examined using a light microscope at 20X magnification (Leica Microsystems, Milan 
Italy). The detection and quantization of ACF, polyps and tumours on the colon were 
performed as previously reported (Izzo et al., 2008). Briefly, in comparison to normal crypts, 
aberrant crypts have greater size, larger and often elongated openings, thicker lining of 
epithelial cells, compression of adjacent crypts, and are more darkly stained with methylene 
blue. Only foci containing four or more aberrant crypts (which are best correlated with the final 
tumour incidence) were evaluated. The criterion to distinguish polyps from tumours was 
established considering the main characteristic features of these two lesions (i.e. crypt 
distortion around a central focus and increased distance from luminal to basal surface of cells 
for polyps and high grade of dysplasia with complete loss of crypt morphology for tumours) 
(Izzo et al., 2008). For polyp and tumour evaluations, the colons of all mice were discolored 
with 70% ethanol and embedded in paraffin; thereafter, 5 micron sections were de-paraffinized 
with xilene, stained with hematoxylin-eosin and observed in a DM 4000 B Leica microscope 
(Leica Microsystems, Milan, Italy).  
3.2.3 Colorectal cancer xenograft model 
Colorectal carcinoma HCT 116 cells (2.5x106) were injected subcutaneously into the right 
flank of each athymic mice for a total volume of 200 µl per injection (50% cell suspension in 
PBS, 50% MatrigelTM). Approximately 10 days after inoculation, mice were received ip the 
pharmacological treatment [CBD (5 mg/kg), CBD BDS (5 mg/kg) and CBG (1-10 mg/kg) were 
given once a day]. Tumour size was measured every day by digital caliper measurements, and 
28 
 
tumour volume was calculated according to the modified formula for ellipsoid volume (volume 
= π/6 × length × width2) (Guo et al., 2006).  
3.2.4 Experimental colitis 
Colitis was induced by the intracolonic administration of DNBS (Borrelli et al., 2009). Briefly, 
mice were anesthetized and DNBS (150 mg/kg) was inserted into the colon using a 
polyethylene catheter (1 mm in diameter) via the rectum (4.5 cm from the anus). Three days 
after DNBS administration, all animals were euthanized by asphyxiation with CO2, the mice 
abdomen was opened by a midline incision and the colon removed, isolated from surrounding 
tissues, opened along the antimesenteric border, rinsed, weighed and length measured (in order 
to determine the colon weight/colon length ratio). For biochemical analyses, tissues were kept 
at −80°C until use, while for histological examination and immunohistochemistry tissues were 
fixed in 10% (v/v) formaldehyde. The dose of DNBS was selected on the basis of preliminary 
experiments showing a remarkable colonic damage associated to high reproducibility and low 
mortality for the 150 mg/kg dose. The time point of damage evaluation (i.e., 3 days after DNBS 
administration) was chosen because maximal DNBS-induced inflammation has been reported 
in mice after 3 days (Massa et al., 2004). Furthermore, previous studies have shown that 3 days 
after intracolonic DNBS administration in mice, the inflammatory response may be modulated 
by administration of cannabinoid drugs (Massa et al., 2004; Borrelli et al., 2009).  
In our experimental design, we have used the curative protocol in which the pCBs tested [i.e. 
CBG (1-30 mg/kg), CBC (0.1 and 1 mg/kg), and THCV (0.3-5 mg/kg)] were injected ip for two 
consecutive days starting 24-h after DNBS administration. 
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3.3 Ex vivo studies 
3.3.1  Cytokines measurement 
Interleukin-1β (IL-1β), interferon-γ (IFN-γ) and interleukin-10 (IL-10 levels) were detected 
both in cell medium and in colonic homogenate. Specifically, their levels were quantified using 
commercial enzyme-linked immunosorbent assay (ELISA) kits (Tema Ricerca Srl, Bologna) 
according to the manufacturer's instructions, in (i) cell medium of LPS-treated peritoneal 
macrophages after 18-h exposure to CBC and THCV (both at 1 µM concentration) and in (ii) 
homogenate obtained from full-thickness colonic tissues of DNBS-induced colitis mice, treated 
or not with CBG (30 mg/kg). 
3.3.2 Histology and immunohistochemistry 
Histological and immunochemistry evaluations have been performed on colonic tissues from 
DNBS-induced colitis mice [treated or not with CBG and CBC given ip (30 mg/kg and 1 
mg/kg, respectively)]. It was performed 3 days after DNBS administration and assessed on a 
segment of 1 cm of colon located 4 cm above the anal canal. After fixation for 24 h in saline 
10% formaldehyde, samples were dehydrated in graded ethanol and embedded in paraffin. 
Thereafter, 5-µm sections were deparaffinized with xylene, stained with hematoxylin–eosin, 
and observed in a DM 4000 B Leica microscope (Leica Microsystems, Milan, Italy). For 
microscopic scoring we used a modified version of the scoring system reported by D’Argenio 
and colleagues. Briefly, colon was scored considering (1) the submucosal infiltration (0, none; 
1, mild; 2–3, moderate; 4–5 severe), (2) the crypt abscesses (0, none, 1–2 rare; 3–5, diffuse) 
and (3) the mucosal  erosion (0, absent; 1, focus; 2-3, extended until the middle of the visible 
surface; 4-5, extended until the entire visible surface) (D’Argenio et al., 2006).  
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For immunohistochemical detection of Ki-67, paraffin-embedded slides were immersed in a 
Tris/ethylenediaminetetraacetic acid buffer (pH 9.0), were heated in a decloaking chamber at 
125°C for 3 min and were cooled at room temperature for 20 min. After adding 3% hydrogen 
peroxide, sections were incubated for 10 min. After washing the sections with Tris-buffered 
saline Tween-20 (pH 7.6), they were stained with rabbit monoclonal antibody to Ki-67 
(Ventana Medical systems, Tucson, Arizona). Briefly, each tissue section was incubated with 
primary antibody to Ki-67 (1:100) for 30 min at room temperature. The slides were washed 
three times with Tris-buffered saline Tween-20 and were incubated with secondary antibody 
for 30 min. After, the slides were reacted with streptavidin for 20 min, the reaction was 
visualized by 3,3’-diaminobenzidine tetrahydrochloride for 5 min. Finally, the slides were 
counterstained with Mayer’s hematoxylin. The intensity and localization of immunoreactivities 
against the primary antibody used were examined on all sections with a microscope (Leica 
Microsystems, Milan, Italy). 
3.3.3 Intestinal permeability 
Intestinal permeability was examined in the serum collected from the blood of healthy mice and 
DNBS-treated mice [in the presence or absence of CBG (30 mg/kg) or CBC (1 mg/kg) ip] 
using a fluorescein isothiocyanate (FITC)-labeled-dextran method, as described by Osanai et 
al., 2007. Briefly, two days after DNBS administration, mice were gavaged with 600 mg/kg 
body weight of fluorescein isothiocyanate (FITC)-conjugated dextran (molecular mass 3-5 
kDa). One day later, blood was collected by cardiac puncture, and the serum was immediately 
analyzed for FITC-derived fluorescence using a fluorescent microplate reader with an 
excitation–emission wavelengths of 485–520 nm (LS55Luminescence Spectrometer, 
PerkinElmer Instruments). Serial-diluted FICT-dextran was used to generate a standard curve. 
Intestinal permeability was expressed as FITC nM found in the serum. 
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3.3.4 Myeloperoxidase (MPO) activity 
Myeloperoxidase (MPO) activity was determined in the colon homogenized from control mice 
and in DNBS-treated  mice [receiving or not CBG (30 mg/kg) or CBC (1 mg/kg), ip] as 
described by Goldblum et al., 1985. Full-thickness colons were homogenized in an appropriate 
lysis buffer [0.5% hexadecyl-trimethylammonium bromide  (HTAB) in 3-(N-
morpholino)propanesulfonic acid (MOPS) 10 mM) in ratio 50 mg tissue /1 ml  MOPS . The 
samples were then centrifuged for 20 minutes at 15,000 x g at 4° C. An aliquot of the 
supernatant was then incubated with sodium phosphate buffer (NaPP buffer pH 5.5) e tetra-
methyl-benzidine 16 mM. After 5 minutes, H2O2 (9.8 M) in NaPP was added  and the reaction 
stopped adding acetic acid. The rate of exchange in absorbance was measured by a 
spectrophotometer at 650 nm. Different dilutions of human MPO enzyme of known 
concentration were used to obtain a standard curve. MPO activity was expressed as units 
(U)/ml. 
3.3.5 Superoxide dismutase (SOD) activity  
A modified version of the Kuthan et al., 1986 method was used to detect SOD activity. Full-
thickness colons from control and DNBS-treated mice (treated or not with CBG 30 mg/kg ip) 
were homogenized in PBS 1X. Homogenates were centrifuged at 25.000 g for 15 min at 4°C. 
Extraction of Cu-Zn SOD was obtained treating the cytosolic lysates with ethanol (1:1) and 
chloroform (1:0.6) at 25°C for 15 min. After centrifugation (15.000 g, 15 min, 4°C), 125 µl of 
the surnatant was incubated (for 20 min) with 613 µl of a reaction mixture containing 0.12 mM 
xanthine, 48 mM Na2CO3, 0.094 mM EDTA, 60 mg/l bovine serum albumin (BSA), 0.03 mM 
nitro blue tetrazolium (NBT), 0.006 U/ml xanthine oxidase. Finally, CuCl2 (0.8 mM) was 
added to stop the reaction. Absorbance readings at 560 nm were recorded using a Beckman 
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DU62 spectrophotometer. Superoxide radical scavenging capacity was expressed as ng 
SOD/mg tissues contained in the lysates. 
3.3.6 Western blot analysis 
Preparation of cytosolic lysates from intestinal tissues  
Full-thickness colons from control,  AOM- and DNBS-treated mice (treated or not with 
phytocannabinoids given ip) were homogenized in lysis buffer (1:2, w/v) containing 0.5 M β-
glycerophosphate, 20 mM MgCl2, 10 mM ethylene glycol tetraacetic acid (EGTA) and 
supplemented with 100 mM dithiothreitol (DTT) and protease/phosphatase inhibitors (100 mM 
dimethylsulfonyl fluoride, 2 mg/ml apronitin, 2 mM leupeptin, and 10 mM Na3VO4). 
Homogenates were centrifuged at 600 g for 5 min at 4°C; the supernatants were collected and 
centrifuged at 16,200 g for 10 min at 4°C. Proteins (50 µg) were determined with the Bradford 
method. 
Preparation of cytosolic lysates from peritoneal macrophages 
Macrophages were collected using the following lysis buffer: 20 mM (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) HEPES, 1.5 mM MgCl2, 400 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid (EDTA) and EGTA, 1% NP-40, 20% glycerol, 1 mM DTT, 0.5 
mM phenylmethanesulfonyl fluoride (PMSF), 15 µg/ml aprotinin, 3 µg/ml pepstatin A, 2 µg/ml 
leupeptin), and centrifuged at 11,200 g for 15 min at 4°C.  Macrophages lysates (50 µg of 
proteins) were determined using the Bradford method. 
Preparation of cytosolic lysates from Caco-2 cells 
Caco-2 cells were collected using the buffer composed by: 50 mM Tris–HCl, pH 7.4, 0.25% 
sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM NaF, 1% NP-40, 1 mM PMSF, 1 
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mM Na3VO4 plus and enriched of a complete protease inhibitor cocktail (Roche Diagnostics, 
Mannheim, Germany). Caco-2 lysates (50-70 µg of proteins) was determined on supernatant 
(following centrifugation at 16,200 g for 15 min) using the Bradford method. 
Measurement of protein expression 
The cytosolic lysates obtained were subjected to electrophoresis on a sodium dodecyl sulphate 
(SDS) 10% polyacrylamide gel and electrophoretically transferred onto a nitrocellulose transfer 
membrane (Protran, Schleicher & Schuell, Germany). Proteins were visualized on the filters by 
reversible staining with Ponceau-S solution (Sigma) and de-stained in PBS containing 0,1 % 
Tween 20. All the membranes obtained were blocked at 4 °C in milk buffer (5% non-fat dry 
milk in PBS/Tween 0.1 %) and then incubated overnight at 4° C with several monoclonal 
primary antibodies, as detailed below: 
i) the homogenates of colonic tissues obtained from control and AOM-treated mice (alone or 
treated with CBD 1 mg/kg ip) were used to investigate the expression of inducible nitric oxide 
synthase (iNOS), cycloxygenase (COX-2), phospho-Akt and caspase-3. The membranes were 
incubated with anti-iNOS, anti-COX-2 (BD Biosciences from Becton Dickinson, Buccinasco, 
Italy), anti-β-actin (Sigma, Milan, Italy), antiphosho- Akt or anti-Akt and anti-cleaved-caspase-
3 (fragment p17) or anti-uncleaved caspase-3 (fragment p30) (Cell Signaling from Euroclone, 
Milan, Italy) to normalize the results, which have been expressed as a ratio of densitometric 
analysis of COX-2/β-actin, iNOS/β-actin, phospho-AKT/AKT and cleaved caspases 3 
(p17)/uncleaved caspase 3 (p30) bands.  
ii) the homogenates of colonic tissues obtained from control and DNBS-treated mice (alone or 
treated with CBG 30 mg/kg 1 mg/kg ip) and the cytosolic fractions from macrophages lysates 
[treated or not with LPS, 1 µg/ml for 18 h and exposed to CBG, CBC and THCV (all at 1 µM 
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concentration)] were used to investigate the involvement of inducible nitric oxide synthase 
(iNOS) and cycloxygenase (COX-2). The immunoblots were incubated with mouse anti-COX-
2 (BD Bioscience, Belgium) and anti-iNOS (Cayman Chemical, USA) and subsequently with 
mouse anti-peroxidase-conjugated goat IgG (Jackson ImmunoResearch from LiStarFish, Milan, 
Italy). The membranes were probed with an anti β-actin antibody to normalize the results, 
which were expressed as a ratio of densitometric analysis of COX-2/β-actin and iNOS/β-actin 
bands. All the antibodies were used according to the dilution instructions reported on the their 
data sheets. All the signals obtained were visualized by enhanced chemiluminescence using 
ImageQuant 400 equipped with software ImageQuant Capture (GE Healthcare, Milan, Italy) 
and analysed using Quantity One Software version 4.6.3.  
3.4 In vitro studies 
3.4.1 Cell culture 
Adenocarcinoma cell lines  
For in vitro experiments, three human colon adenocarcinoma cell lines (i.e. Caco-2, DLD-1 and 
HCT116 cells, ATCC from LGC Standards, Milan, Italy), with a different genetic profile (APC 
gene mutated in Caco-2 cells, K-RAS mutated in HCT 116 cells, p53 gene mutated in DLD-1 
cells) (Rodrigues et al., 1990; Fukuyama et al., 2008; Dunn et al., 2011) have been used. These 
cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% 
foetal bovine serum (FBS), 100 U/ml penicillin and 100 µg/ml streptomycin, 1% non-essential 
amino acids, 2 mM L-glutamine and 1 M HEPES, in conformity with the manufacturer’s 
protocols. Cell viability was evaluated by trypan blue exclusion.  
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Healthy colonic epithelial cells (HCEC) 
The immortalized epithelial cells derived from human colon biopsies, the healthy human 
colonic epithelial cells (HCEC) have been used as a comparison with tumoural cells. HCEC, 
from Fondazione Callerio Onlus (Trieste, Italy), were cultured in Dulbecco's modified Eagle’s 
medium (DMEM) supplemented with 10% FBS, 100 Units/ml penicillin, 100 µg/ml 
streptomycin, 200 mM L-Glutamine, 100 mM Na-pyruvate and 1 M HEPES. Cell viability was 
evaluated by trypan blue exclusion.  
Human CB1/CB2 chinese hamster ovarian (CHO) cells 
For radioligand binding assays, chinese hamster ovarian (CHO) cells, stably transfected with 
complementary DNA encoding human cannabinoid CB1 receptors and human cannabinoid CB2 
receptors, were cultured in Eagle’s medium nutrient mixture F-12 Ham supplemented with 1 
mM L-glutamine, 10% v/v FBS and 0.6% penicillin-streptomycin together with geneticin (600 
mg/mL). These CHO-hCB1/hCB2 cells were passaged twice a week using a non-enzymatic cell 
dissociation solution. 
Mouse peritoneal macrophages  
The peritoneal cavity is a membrane-bound and fluid-filled abdominal cavity of mammals that 
harbors a number of immune cells including macrophages, B cells and T cells. The presence of 
a high number of naïve macrophages in the peritoneal cavity makes it a preferred site for the 
collection of naïve tissue resident macrophages (Zhang et al., 2008). Briefly, to evoke the 
production of peritoneal exudates rich in macrophages, mice were injected ip with 1 ml of 10% 
(w/v) sterile thioglycollate medium (Sigma, Milan, Italy). After 4 days, mice were killed and 
the peritoneal macrophages were collected and seeded in appropriate plates for performing in 
vitro experiments (Aviello et al., 2011). 
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Peritoneal macrophages were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FBS, 100 Units/ml penicillin, 100 µg/ml streptomycin, 200 mM L-
Glutamine, 100 mM Na-pyruvate and 1 M HEPES. Cell viability was evaluated by trypan blue 
staining. The inflammatory response in peritoneal macrophages was induced by 
lipopolysaccharides (LPS) from Escherichia coli serotype O111:B4 (1 µg/ml). The acute 
inflammatory response in macrophages required an LPS incubation time of 18 h (Aviello et al., 
2011). 
For all the cell lines described the medium was changed every 48 h in conformity with the 
manufacturer’s protocols. 
3.4.2 Cytotoxicity assays 
Cytotoxicity assays were performed using MTT assay and the neutral red assays: 
MTT assay:  
Cell respiration was assessed by the mitochondrial dependent reduction of 3-(4,5-
dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan (Mosmann, 1983). 
After incubation with the tested compounds for 24 hours cells, seeded in a 96-well plates with a 
cellular density depending on the cell type (see following), were incubated with MTT (250 
µg/ml) for 1 h. After solubilisation in DMSO, the extent of reduction of MTT to formazan was 
quantitated by measuring the optical density at 490 nm (iMarkTM Microplate Assorbance 
Reader, BioRad). Treatments were compared with a reference cytotoxic drug (DMSO 20% 
v/v). Results are expressed as a percentage of the corresponding controls (without treatment), 
(n=3 experiments including 8-10 replicates for each experiment). 
CBC (0.001-1 µM), the CB1 receptor agonist ACEA (0.001-0.1 µM), the CB2 receptor agonist 
JWH133 (0.001-0.1 µM), the CB1 receptor antagonists rimonabant (0.1 µM) and AM251 (1 
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µM) and the CB2 receptor antagonist SR 144528 (0.1 µM) were incubated for 24 hours for the 
evaluation of macrophage mitochondrial respiration.  
CBG (1-30 µM) was incubated on Caco-2 and HCEC cells with medium containing 1% for 24 
hours. The cytotoxic effect of CBG (10 µM) was evaluated in the presence of  AM251 (1 µM, 
CB1 receptor antagonist), AM630 (1 µM, CB2 receptor antagonist) or ruthenium red (10 and 
25µM, a non-selective TRP antagonist], all incubated 30 min before CBG.  
CBD (1-30 µM), CBDV (1-30 µM), CBC (1-30 µM,), AMTB (5-50 µM, TRPM8 receptor 
antagonist) and WAY100635 (0.2 and 1 µM, 5HT1A receptor antagonist) were incubated (with 
1% FBS medium for 24 hours) for the evaluation of Caco-2 cell viability.  
Neutral Red (NR) assay: 
The NR assay system, one of the most used and sensitive cytotoxicity test, is a mean of 
measuring living cells via the uptake of the vital dye neutral red. After incubation with the 
tested compounds for 24 h cells, seeded in a 96-well plate with a cellular density depending on 
the cell type (see following), were incubated with NR dye solution (50 µg/ml) for 3 h (Aviello 
et al., 2011). Cells were lysed with 1% (v/v) acetic acid, and the absorbance was read at 532 
nm (iMarkTM microplate absorbance reader, BioRad). Dimethyl sulphoxide (DMSO, 20%, 
v/v) was used as a positive control. The results are expressed as percentage of cell viability, 
(n=3 experiments including 8-10 replicates for each experiment). 
CBD (at the concentration range of 0.01-10 µM) was incubated for 24 hours for the evaluation 
of Caco-2, HCT 116, DLD-1  and HCEC cells viability. 
CBD BDS (1-5 µM) was incubated for 24 hours for the evaluation of HCT 116, DLD-1  and 
HCEC cells viability. 
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Cells were seeded in 96-well plates with the following cellular density per well and the 
adhesion time was 48 hours for all the cell lines used excepting for peritoneal macrophages, 
allowed to adhere for 3 hours: 
HCT 116 and DLD-1 (tumoral cell lines): 2.5×103 cells per well; Caco-2 (tumoral cell line): 
1.0×104 cells per well; HCEC (healthy colonic epithelial cells): 1.0×104 cells per well; 
peritoneal macrophages: 1×105 cells per well  
3.4.3 DNA damage assay (comet assay) 
Genotoxicity studies were performed by single cell electrophoresis assay (comet assay) 
(Aviello et al., 2010). Following 24 hours exposure to CBD (10 µM), Caco-2 cells were 
incubated with 75 µM H2O2 (damaging stimulus) or phosphate-buffered saline PBS 
(undamaging stimulus) for 5 min. After centrifugation at 1,000 g for 5 min, pellets were mixed 
with 0.85% low melting point agarose and added to 1% normal melting point agarose gels. 
Gels were then suspended in 2.5 M NaCl, 100mM Na2EDTA, 10 mM Tris and 1% Triton X-
100, pH 10 at 4°C for 1 h and electrophoresed in alkaline buffer (300mM NaOH, 1 mM 
Na2EDTA, pH 12) at 26 V, 300 mA for 20 min. After neutralisation in 0.4 M Tris–HCl (pH 
7.5), gels were stained with 2 µg/ml ethidium bromide. Images were analysed using a Leica 
microscope equipped with a Casp software. 
3.4.4 Identification and quantification of endocannabinoids and related molecules 
Endocannabinoids, anandamide and 2-arachidonoylglycerol (2-AG), palmitoylethanolamide 
(PEA) and oleoylethanolamide (OEA) levels were measured in Caco-2 cells exposed to CBD 
(10 µM) for 24 h and in peritoneal macrophages (treated or not with LPS, 1 µg/ml for 18 h) and 
exposed to CBC (1 µM), added 30 min before LPS challenge. Cells were harvested in 70% 
methanol before cell processing, subsequently extracted, purified and analysed by isotope 
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dilution liquid chromatography-atmospheric pressure-chemical ionisation mass spectrometry 
(Izzo et al., 2008). 
3.4.5 Intracellular reactive oxygen species (ROS) measurement assay 
Generation of intracellular reactive oxygen species (ROS) was estimated by the fluorescent 
probe, 2′,7′-Dichlorofluorescin diacetate (DCFH-DA) which diffuses readily through the cell 
membrane. In the cells, DCFH-DA is before enzymatically hydrolyzed by intracellular 
esterases to form non-fluorescent DCFH and then rapidly oxidized to form highly fluorescent 
dichlorofluorescein (DCF) in the presence of ROS. The DCF fluorescence intensity is 
paralleled to the amount of ROS formed intracellularly. Caco-2 cells and HCEC were plated in 
96-well black plates at the density of 1×104 cells/well (Aviello et al., 2011). After 48 h, the 
cells were incubated with a medium containing 1% FBS in presence or absence of CBG (10 
µM, for 24-hours). After washing, cells were incubated for 1 hour with 200 µl of 100 µM 
H2DCF-DA in HBSS containing 1% FBS. The Fenton’s reagent (H2O2/Fe2+ 2 mM, 3 hours), 
was used as a positive control. 
The DCF fluorescence intensity was detected using a fluorescent microplate reader (Perkin-
Elmer Instruments), with the excitation wavelength of 485 nm and the emission wavelength of 
538 nm. The intracellular ROS levels were expressed as fluorescence intensity (picogreen). 
3.4.6 Measurement of caspases 3/7 activity 
Apoptosis was evaluated by means of the Caspase-Glo®3/7 Chemiluminescence Assay Kit 
(Promega Corporation, Madison, WI, USA) following the manufacturer’s protocol. Caco-2 
cells were seeded in 12-well plates at a density of 5x104 cells/well. After 48 hours, the cells 
were incubated with medium containing 1% FBS in presence or absence of CBG (10 µM, for 
24 hours). After incubation, cells were trypsinized, washed with PBS and processed. The assay 
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was performed in 96-well white walled plates, adding to each well 100 µL of Caspase-Glo® 3/7 
reagent to 100 µL of culture medium containing 5-40 µl of cells suspension (about 1000 
cells/µl) in culture medium. The cell suspension concentration was evaluated by a cell counter 
(Bioad TC10TM) and confirmed by a DNA assay (Quant-it DNA assay kit, Invitrogen) 
considering 4 pg DNA/cell. After 1 h incubation in the dark at room temperature, 
chemiluminescence was measured by a VersaDoc MP System (Bio-Rad) equipped by the 
Quantity One® version 4.6 software. All samples were assayed in triplicate. 
Chemiluminescence mean values were plotted versus the cell number in the assay and the 
linear regression curve fit was calculated by the software (Excell-Windows). The increase of 
caspase 3/7 enzymatic activity was calculated by the ratio of the curve slopes. 
3.4.7 Morphological assessment of apoptotic and necrotic cells 
Cells were seeded on glass disk (1.3 cm in diameter) placed into wells of a 24-well plate, at a 
density of 5xl04 cell/disk, for 48 hours and thereafter treated with a medium containing 1% 
FBS in presence or absence of CBG (10 µM, for 24-h). After incubation, the culture medium 
was removed, the glass disks were collected and pasted on slide. Subsequently, cells on slides 
were fixed and stained by the standard hematoxylin-eosin method. The slides were analyzed 
and the histological images were captured with the aid of a light microscope (at 200 X 
magnification). The number of apoptotic and necrotic cells was quantified using at least 100 
cells per slide (n=3 independent experiments). 
3.4.8 Nitrites measurement 
Nitrites, stable metabolites of NO, were measured in macrophages medium as previously 
described (Aviello et al., 2011). Mouse peritoneal macrophages (5×105 cells per well seeded in 
a 24-well plate) were incubated with the drugs tested (see following) for 30 min and 
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subsequently with LPS (1 µg/ml) for 18 h. After reduction of nitrates to nitrites by cadmium, 
cell supernatants were incubated with 2,3-diaminonaphtalene (DAN) (50 µg/ml) for 7 min. 
After stopping the reaction with 2.8 N NaOH, nitrite levels were measured using a fluorescent 
microplate reader (LS55 Luminescence Spectrometer, PerkinElmer Instruments, excitation–
emission wavelengths of 365–450 nm).  
For the evaluation of nitrite levels, mouse peritoneal macrophages were incubated with CBG, 
CBC and THCV (0.001–1 µM) in presence or not of LPS (1 µg/ml) for 18 hours. In a 
subsequent set of experiments, rimonabant (0.1 µM, CB1 receptor antagonist) and SR144528 
(0.1 µM, CB2 receptor antagonist) were incubated 30 min before CBG, CBC and/or THCV (1 
µM) + LPS (1 µg/ml) for 18 hours. 
In some experiments, cells were also treated with ACEA (0.001-0.1 µM, CB1 agonists) and 
JWH133 (0.001-0.1 µM, CB2 receptor agonist) incubated 30 min before LPS stimulation. 
3.4.9 Proliferation assays:  
Proliferation assays were performed using MTT assay and the 3H-thymidine incorporation: 
3H-thymidine incorporation 
Cell proliferation was evaluated in colorectal carcinoma cell line Caco-2 using the 3H-
thymidine incorporation as previously described (Aviello et al., 2010). Briefly, Caco-2 cells 
were seeded in 24-well plates at a density of 1.0x104 in DMEM supplemented with 10% FBS 
and grown for 24 hours. The resulting monolayers were washed three times with phosphate 
buffered saline (PBS) and then 1 ml of serum-free DMEM was added to each well. After 24 
hours of serum starvation, the cells were washed three times with PBS and incubated with 
DMEM supplemented with 10% FBS containing CBD (0.01–10 µM) in the presence of 
[methyl-3H]-thymidine (1 µCi/well) for 24 hours, scraped in 1 M NaOH and collected in 
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plastic miniature vials (PerkinElmer) filled up with liquid for scintillation counting 
(UltimaGold® PerkinElmer). Treatments were compared with 300 µM spermine. Cell 
proliferation was expressed as count per minute on µg of protein (CPM/µg protein) of 
incorporating 3H-thymidine cells using a β-counting (PerkinElmer, Milan, Italy). The 
treatments were carried out in triplicate and three independent experiments were performed. 
The protein content was quantified using the Bradford method. 
MTT assay  
The MTT assay, beyond its use as a cytotoxicity assay, can also be used for the evaluation of 
cell proliferation. For this purpose, it is necessary to synchronize cells at the same cellular cycle 
phase (G1/Go) by serum deprivation (i.e. starvation). Caco-2 (at a density of 1.0x104), HCT116, 
DLD-1 (both at a density of 2.5x103) and HCEC (at a density of 1.0x104) cells were seeded, 
allowed to adhere for 48 hours and starved by serum deprivation for 24 h. Briefly, for the MTT 
assay, cells were treated with CBD (0.01–10 µM in Caco-2 HCT116, DLD-1 and HCEC), CBD 
BDS, (0.3-5 µM in HCT116, DLD-1 and HCEC cells) for 24 h and incubated with MTT (250 
µg/ml) for 1 h at 37°C. The mitochondrial reduction of MTT to formazan was then quantitated 
at 490 nm (iMarkTM microplate reader, BioRad, Italy). Using this assay, the antiproliferative 
effect of CBD and CBD BDS was evaluated in Caco-2 and DLD-1 cells in the presence of 
several selective receptor antagonists all incubated 30 min before the addition of CBD or CBD 
BDS. 
3.4.10 Radioligand [35S] GTPγS binding assay  
Binding assays with [35S] guanosine 5''-(gamma-thio)triphosphate (GTPγS) were performed 
with CB1-CHO cell membranes. The cells were removed from flasks by scraping and then 
frozen as pellets at -20ºC until required. Before use in a radioligand binding assay, cells were 
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defrosted, diluted in Tris-buffer (50 mM Tris-HCl, 50 mM Tris-Base) and homogenized. 
Protein assays were performed using a Bio-Rad Dc kit (Hercules, CA).  
Measurement of agonist-stimulated [35S]GTPγS binding to cannabinoid CB1 receptors was 
described previously (Brown et al., 2010). The assays were carried out with GTPγS binding 
buffer (50 mM Tris-HCl, 50 mM Tris-Base, 5 mM MgCl2, 1 mM EDTA, 100 mM NaCl, 1 mM 
DTT and 0.1% bovine serum albumin) in the presence of [35S]GTPγS and guanosine 
diphosphate (GDP), in a final volume of 500 µl. Binding was initiated by the addition of 
[35S]GTPγS to the wells. Non-specific binding was measured in the presence of 30 µM GTPγS. 
The cannabinoid receptor antagonist rimonabant (0.1µM) was incubated 30 min before CBC 
(1µM), at 30ºC. Total incubation time was 60 min. The reaction was terminated by a rapid 
vacuum filtration method using Tris-binding buffer, as described previously, and the 
radioactivity was quantified by liquid scintillation spectrometry. In all the [35S]GTPγS binding 
assays, we used 0.1 nM [35S]GTPγS, 30 µM GDP and 33 µg per well of proteins.  
3.4.11 Radioligand displacement assay 
Displacement assay was performed with membranes from CHO cells transfected with human 
CB1 or CB2 receptors (Ross et al., 2000). The CHO cells were removed from flasks by scraping 
and then frozen as a pellet at -20°C until required. Before use in a radioligand binding assay, 
cells were defrosted, diluted in 50 mM Tris buffer and homogenized with a 1 ml hand-held 
homogenizer. Protein assays were performed using a Bio-Rad Dc kit (Bio-Rad, Hercules, CA, 
USA). The assay was carried out, as previously described by Ross et al., 2000, with 
[3H]CP55940, 50mM Tris HCl, 50 mM Tris Base and 1 mg/ml BSA (assay buffer), total assay 
volume 500 µl. CBD, CBD BDS (0.0001-10 µM) and [3H]CP55940 were each added in a 
volume of 50 µl following their dilution in assay buffer. Binding was initiated by the addition 
of hCB1- or hCB2-CHO cell membranes (25 µg protein per tube) and all assays were performed 
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at 37°C for 60 min before termination by the addition of ice-cold wash buffer (50 mM Tris 
buffer, 1 mg/ ml BSA) and vacuum filtration using a 24-well sampling manifold (Brandel Cell 
Harvester) and Whatman GF/B glass-fibre filters that have been soaked in wash buffer at 4°C 
for 24h. Each reaction tube was washed three times with a 4 ml aliquot of buffer. The filters 
were oven-dried for 60 min and then placed in 5 ml of scintillation fluid (Ultima Gold XR, 
Packard). Radioactivity was quantified by liquid scintillation spectrometry. Specific binding 
was defined as the difference between the binding that occurs in the presence and absence of 1 
µM unlabeled CP55940. The concentration of [3H]CP55940 used in the displacement assays 
was 0.7 nM. 
3.4.12 Quantitative (real-time) RT-PCR analysis 
Total RNA was extracted according to the manufacturer’s recommendations and further 
purified and DNA digested by the Micro RNA purification system (Invitrogen). Total RNA 
eluted from spin cartridge was UV-quantified by a Bio-Photometer® (Eppendorf, Santa Clara, 
CA, USA), and purity of RNA samples was evaluated by the RNA-6000-Nano® microchip 
assay using a 2100 Bioanalyzer® equipped with a 2100 Expert Software® (Agilent, Santa Clara, 
CA, USA) following the manufacturer’s instructions. For all samples tested, the RNA integrity 
number was greater than 8 relative to a 0–10 scale. One microgram of total RNA, as evaluated 
by the 2100 Bioanalyzer, was reverse transcribed in cDNA by the SuperScript III SuperMix 
(Invitrogen). The reaction mixture was incubated in a termocycler iCycler-iQ5® (Bio-Rad, 
Hercules, CA, USA) for a 5 min at 60°C step, followed by a rapid chilling for 2 min at 4°C. 
The protocol was stopped at this step and the reverse transcriptase was added to the samples, 
except the negative controls (–RT). The incubation was resumed with two thermal steps: 10 
min at 25°C followed by 40 min at 50°C. Finally, the reaction was terminated by heating at 
95°C for 10 min. Quantitative real time PCR was performed by an iCycler-iQ5® in a 20mL 
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reaction mixture containing 1 X SYBR green supermix (Bio-Rad), 10 ng of cDNA (calculated 
on the basis of the retro-transcribed RNA) and 330 nM for each primer. Primer sequences and 
optimum annealing temperature (TaOpt) were designed by the AlleleID software 
(PremierBiosoft). The amplification profile consisted of an initial denaturation of 2 min at 94°C 
and 40 cycles of 30 s at 94°C, annealing for 30 s at TaOpt and elongation for 45 s at 68°C. 
Fluorescence data were collected during the elongation step. A final melt-curve data analysis  
was also included in the thermal protocol. Assays were performed in quadruplicate (maximum 
Ct of replicate samples <0.5), and a standard curve from consecutive fivefold dilutions (100 to 
0.16 ng) of a cDNA pool representative of all samples was included for PCR efficiency 
determination. Relative normalized expression was evaluated as previously described (Di 
Marzo et al., 2008). For the targets evaluated in the colorectal cancer cells and human healthy 
colonic epithelial cell line a qualitative arbitrary scale to define the level of  mRNA expression 
was considered as follows: high expression (HE) from 20 to 25 Cq; middle expression (ME) 
from 25 to 30 Cq; low expression (LE) from 30 to 33Cq, very low expression (VLE) over 
33Cq. Furthermore two quality  parameters have been utilized in evaluating expression data: i) 
the maximum acceptable standard deviation  for replicate samples was put ≤ 0.500 (note that at 
high Cq the standard deviation normally draws to increase); ii) the expression data is significant 
if ∆ (Cqmean-Cqbkg) ≥  5.  Assays were performed in quadruplicate in two independent 
experiments, by using 20 ng of cDNA (as evaluated from the input RNA used for reverse-
transcription). 
The targets investigated were: 
i) CB1, CB2, TRPA1, TRPV1, TRPV2, TRPM8 and 5HT1A mRNA expression in colorectal 
carcinoma cell line (Caco-2) and human healthy colonic epithelial cell line (HCEC) 
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ii) CB1, CB2, iNOS and COX-2 mRNA expression in peritoneal macrophages (treated or not 
with CBC and/or CBG 1 µM, 30 min before LPS)  
All the cell lines used were collected and homogenized in 1.0 mL of Trizol® (Invitrogen). 
3.5 Statistical analysis 
Statistical analysis has been carried out using GraphPad Prism 5.0 (GraphPad Software, San 
Diego, CA, USA). Data are expressed as the mean ± standard error (SEM) or standard 
deviation (SD) of n experiments. To determine statistical significance, Student's t test was used 
for comparing a single treatment mean with a control mean, and an one-way analysis of 
variance followed by a Tukey-Kramer multiple comparisons test was used for analysis of 
multiple treatment means. ANOVA was used to compare different concentration-effect curves 
with P<0.05 considered significant. The IC50 (concentration that produced 50% inhibition of 
cell viability) value was calculated by nonlinear regression analysis using the equation for a 
sigmoid concentration–response curve (GraphPad Prism). P values < 0.05 were considered 
significant.  
Values obtained from the radioligand assays have been expressed as means and variability as 
SEM or as 95% confidence limits. Net agonist stimulated [35S]GTPγS binding values were 
calculated by subtracting basal binding values (obtained in the absence of agonist) from 
agonist-stimulated values (obtained in the presence of agonist) as detailed elsewhere (Brizzi et 
al., 2005). Values for EC50, maximal effect (Emax) and SEM or 95% confidence limits of these 
values have been calculated by nonlinear regression analysis using the equation for a sigmoid 
concentration-response curve (GraphPad Prism). The concentration of a drug that produces a 
50% displacement of [3H]CP55940 from specific binding sites (IC50) is calculated using 
GraphPad Prism 5. Its dissociation constant (Ki value) is calculated using the equation of Cheng 
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and Prusoff (1973). The parameters for [3H]CP55940 binding to hCB1 and hCB2 CHO cell 
membranes have been determined by fitting data from saturation binding experiments to a one-
site saturation plot using GraphPad Prism 5. They are 57.00 pmol/mg and 215 pmol/mg (Bmax), 
and 1.1 nM and 4.3 nM (Kd) in hCB1 and hCB2 CHO cell membranes, respectively. 
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4.0 RESULTS 
4.1 INFLAMMATORY BOWEL DISEASE (IBD) 
4.1.1 CANNABIGEROL (CBG) 
4.1.1.1 Effect of CBG on colon weight/colon length ratio 
DNBS administration caused a significant increase in colon weight/colon length ratio, a simple 
and reliable marker of intestinal inflammation/damage (Gálvez et al., 2000). CBG (1-30 
mg/kg) given after the inflammatory insult, significantly reduced the effects of DNBS on colon 
weight/colon length ratio. Significant protection was achieved starting from the 5 mg/kg 
(Figure 6).  
4.1.1.2 Effect of CBG on histological damage and inflammation 
Histological evaluations of colonic mucosa of healthy control animals showed normal 
appearance with intact epithelium (Figure 7A). In the DNBS group, colons showed tissue 
injury which was mainly characterized by necrosis involving the full thickness of the mucosa, 
infiltrations of granulocytes into the mucosa/sub-mucosa and oedema of sub-mucosa (Figure 
7B). CBG (30 mg/kg, given after the inflammatory insult) reduced the signs of colon injury 
(microscopic score: control, 0.50±0.22; DNBS, 9.0±0.45#; CBG 30 mg/kg,  6.0±0.45*, n=4, 
#p<0.001 vs control and *p<0.01 vs DNBS alone). In the colon of CBG (30 mg/kg)-treated 
animals, the glands were regenerating, the oedema in sub-mucosa was reduced, and the erosion 
area was superficial (Figure 7C).  
4.1.1.3 Effect of CBG on immunohistochemical detection of Ki-67  
The curative action of CBG was further confirmed by immunohistochemistry. In normal 
colonic mucosa, the predominant area of cell proliferation is localized to the lower of the crypts 
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as revealed by Ki-67 distribution (Figure 8A). In the colon from DNBS-treated mice, total 
necrosis with Ki-67 immunoreactivity on inflammatory cells and in a few remaining surface 
elements was observed (Figure 8B). CBG (30 mg/kg, given after the inflammatory insult) 
partially counteracted the effect of DNBS on cell proliferation, its mitotic activity being 
restricted to the lower half of the mucosa (i.e. the mature superficial cells were not in a 
proliferative state)  (Figure 8C). 
4.1.1.4 Effect of CBG on intestinal barrier function 
FITC-conjugated dextran presence (index of membrane integrity) was not detected in the serum 
of healthy control animals. The administration of DNBS induced FITC-conjugated dextran 
appearance in the serum. CBG treatment (30 mg/kg) completely abolished DNBS-induced 
increased intestinal permeability (Figure 9A).   
4.1.1.5 Effect of CBG on neutrophil infiltration in inflamed colon 
MPO activity is considered to be an index of neutrophil infiltration (because MPO is 
predominantly found in these cells) and it is largely used to quantify intestinal inflammation 
(Krawisz et al., 1984). DNBS-induced colitis was associated with significantly increased 
neutrophil infiltration, as evaluated by MPO  (Figure 9B). CBG, given after the inflammatory 
insult at the dose of 30 mg/kg, counteracted DNBS-induced increase in MPO activity (Figure 
9B). 
4.1.1.6 Effect of CBG on SOD activity in inflamed colon  
DNBS produced a significant decrease in SOD activity. CBG, at the dose of 30 mg/kg, 
counteracted DNBS-induced reduction in SOD activity (Figure 9C).  
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4.1.1.7 Effect of CBG on iNOS and COX-2 protein expression in inflamed colon  
Densitometric analysis indicated a significant increase in the expression of both iNOS and 
COX-2 in the inflamed colons (Figure 10 A-B). CBG (30 mg/kg) reduced iNOS (Figure 10A), 
but not COX-2 (Figure 10B) over-expression induced by DNBS. 
4.1.1.8 Effect of CBG on IL-1β, IL-10 and interferon-γ in the inflamed colon 
The levels of IL-1β and interferon-γ (IFN- γ) were significantly increased by DNBS (Figure 11 
A and B). By contrast, IL-10 production significantly decreased in the colon from DNBS-
treated mice (Figure 11C). Treatment with CBG (30 mg/kg) counteracted the changes in IL-1β, 
IL-10 and IFN-γ levels observed in the inflamed colons (Figure 11A-C). 
4.1.1.9 Cytotoxicity assay on murine peritoneal macrophages 
Cytotoxicity was evaluated performing the MTT assay and CBG, at the concentrations ranging 
from 0.001 to 1 µM, did not affect mitochondrial respiration (expressed as percentage of 
viability ± SEM) after 24-h exposure: [control 99.93 ± 3.69; CBG 0.001 µM 95.58 ± 4.21; 
CBG 0.01 µM 95.58 ± 1.21; CBG 0.1 µM 102.3 ± 4.12; CBG 1 µM 105.60 ± 3.73; CBG 10 
µM 38.23 ± 2.96#; #p<0.001 vs control (n=3 experiments)]. Similarly, the CB1 receptor 
antagonist rimonabant (0.1 µM) and the CB2 receptor antagonist SR144528 (0.1 µM) did not 
exert cytotoxic effects (data not shown).  
4.1.1.10 Effect of CBG on nitrite production in macrophages alone and in presence of 
CB1/CB2 receptor antagonists  
LPS (1 µg/ml for 18 h) administration caused a significant increase in nitrite production (Figure 
12A). A pre-treatment with CBG (0.001-1 µM, 30 min before LPS) caused a significant 
reduction in nitrite production. Since CBG can inhibit endocannabinoid metabolism and hence 
51 
 
indirectly activate cannabinoid receptors (De Petrocellis et al., 2011), in the second set of 
experiments we verified if CBG effect on nitrite production was sensitive to selective CB1 and 
CB2 receptor antagonists. We found that rimonabant (0.1 µM, CB1 receptor antagonist) did not 
modify the inhibitory effect of CBG (1 µM) (Figure 12B). By contrast, SR144528 (0.1 µM, 
CB2 receptor antagonist) enhanced the inhibitory effect of CBG (1 µM) on nitrite production 
(Figure 12C). Rimonabant and SR144528, at the concentrations used, did not modify per se 
nitrite levels induced by LPS stimulation (Figure 12B and C). 
4.1.1.11 Effect of CBG on iNOS and COX-2 (mRNA and protein) expression in LPS-
treated murine peritoneal macrophages 
The inhibitory effect of CBG (1 µM) on nitrite production in LPS-treated macrophages was 
accompanied by decrease of iNOS protein with no significant changes in its transcriptional 
levels (i.e. of iNOS mRNA) (Figure 13A and C). COX-2 is a key enzyme involved in the 
macrophages function. Similarly to iNOS, LPS administration caused up-regulation of COX-2 
mRNA and protein expression. CBG (1 µM) incubated 30 min before LPS stimulation, did not 
modify LPS-induced COX-2 up-regulation (Figure 13B and D). 
4.1.1.12 Effect of CBG on CB1/CB2 mRNA expression in macrophages 
A challenge with LPS (1 µg/ml for 18 h) caused up-regulation of CB1 receptors and down-
regulation of CB2 receptors (Figure 14A and B). CBG (1 µM) did not modify cannabinoid CB1 
and CB2 receptor mRNA expression both in control and in LPS-treated macrophages (Figure 
14A and B).  
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Figure 6. Dinitrobenzene sulfonic acid (DNBS)-induced colitis in mice. Colon weight/length ratio of 
colons from untreated and DNBS-treated mice in the presence or absence of cannabigerol (CBG). 
Tissues were analyzed 3 days after vehicle or DNBS (150 mg/kg, intracolonically) administration. CBG 
(1-30 mg/kg) was administered (ip) once a day for two consecutive days starting 24-h after the 
inflammatory insult. Bars are mean ± SEM of 12-15 mice for each experimental group. #p<0.001 vs 
control, *p<0.05 and **p<0.01 vs DNBS alone. 
 
 
 
 
 
 
 
Control 0 1 5 30
0
10
20
30
40
50
60
70
**
#
*
CBG [mg/kg]
DNBS
co
lo
n
 
w
ei
gh
t/
co
lo
n
 
le
n
gt
h
ra
tio
(m
g/
cm
)
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Histological evaluations of inflamed and non-inflamed colons: effect of cannabigerol (CBG). 
No histological modification was observed in the mucosa and sub-mucosa of control mice (A); mucosal 
injury induced by dinitrobenzene sulfonic acid (DNBS) administration (B); treatment with CBG 
reduced colon injury by stimulating regeneration of the glands (C). Histological analysis was performed 
3 days after DNBS administration. CBG (30 mg/kg) was administered (ip) for two consecutive days 
starting 24-h after the inflammatory insult (curative protocol). Original magnification x200 . The figure 
is representative of 4 experiments. 
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Figure 8. Different patterns of Ki-67 immunoreactivity in the colonic mucosa of control mice (A), 
dinitrobenzene sulfonic acid (DNBS)-treated mice (B) and mice treated with DNBS plus 
cannabigerol(CBG) (C). (A) Ki-67 immunopositive cells were localised to the lower part of the crypts. 
(B) Ki-67 immunopositive cells were observed on inflammatory cells. (C) Ki-67 immunopositive cells 
were observed only in the expanded basal zone. CBG (30 mg/kg) was administered (ip) for two 
consecutive days starting 24-h after the inflammatory insult. The figure is representative of 4 
experiments. 
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Figure 9. Effect of cannabigerol (CBG) on intestinal permeability (evaluated as FITC-dextran 
permeability) (A) , myeloperoxidase (MPO) activity (B) and superoxide dismutase (SOD) activity (C) 
in dinitrobenzene sulfonic acid (DNBS)-induced colitis in mice. Colons (for MPO and SOD activities) 
and blood (for intestinal permeability) were analysed 3 days after vehicle or DNBS (150 mg/kg, 
intracolonically) administration. CBG (30 mg/kg) was administered (ip) for two consecutive days 
starting 24-h after the inflammatory insult (curative protocol). Bars are mean±SEM of 5 mice for each 
experimental group. #p< 0.001 vs control and ***p< 0.001 vs DNBS alone. 
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Figure 10. Inducible nitric oxide synthase (iNOS) (A) and cyclooxygenase-2 (COX-2) (B) expression 
in colonic tissues of animals treated or not with dinitrobenzene sulfonic acid (DNBS): effect of 
cannabigerol (CBG). Measurements were performed 3 days after DNBS (150 mg/kg, intracolonically) 
administration. CBG (30 mg/kg) was administered (ip) for two consecutive days starting 24-h after the 
inflammatory insult. Results are mean±SEM of 3–4 experiments.*p<0.05 and #p< 0.001 vs control; ***p< 
0.001 vs DNBS alone. 
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Figure 11. Effect of cannabigerol (CBG) on interleukin-1β (IL-1β) (A), interferon γ (IFN-γ) (B) and 
interleukin-10 (IL-10) (C) levels in mouse colons treated with dinitrobenzene sulfonic acid (DNBS). 
Measurements were performed 3 days after DNBS (150 mg/kg, intracolonically) administration. CBG 
(30 mg/kg) was administered (ip) for two consecutive days starting 24-h after the inflammatory insult. 
Results (expressed as picograms per ml of proteic extract) are mean± SEM of 3–4 experiments. 
#p<0.01–0.001 vs control, *p< 0.05 and**p< 0.01 vs DNBS alone. 
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Figure 12. Effect of cannabigerol (CBG) on nitrite levels (A) in the cell medium of murine peritoneal 
macrophages incubated with lipopolysaccharide (LPS, 1 mg/ml) for 18 h. CBG (0.001–1 µM) was 
added to the cell media 30 min before LPS challenge. B and C show the effect of CBG, (1 µM) alone or 
in presence of the cannabinoid CB1 receptor antagonist rimonabant (Rim, 0.1 µM) (B) or the 
cannabinoid CB2 receptor antagonist SR144528 (0.1 µM) (C) on nitrite levels in the cell medium of 
murine peritoneal macrophages incubated with LPS (1 µg/ml) for 18 h. The antagonists were added to 
the cell media 30 min before CBG exposure. LPS was incubated 30 min after CBG. Results are 
means±SEM of three experiments (in triplicates). #p<0.001 vs control; *p< 0.05 and ***p< 0.001 vs LPS 
alone; °p< 0.001 vs LPS + CBG. 
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Figure 13. Inducible nitric oxide synthase (iNOS) (A, C) and cyclooxygenase-2 (COX-2) (B, D) protein 
and mRNA levels in cell lysates from macrophages incubated or not with lipopolysaccharide (LPS, 1 
mg/mL) for 18 h. mRNA expression was evaluated by RT-PCR. The expression levels, normalized with 
respect to the reference genes, were scaled to the expression value of the control, considered as 1. 
Protein expression was evaluated by Western blot analysis. Cannabigerol (CBG, 1 µM) was added to 
the cell media 30 min before LPS challenge. #p< 0.001 versus control; **p<0.01 vs LPS (n = 4–5 
experiments). 
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Figure 14. Relative mRNA expression of cannabinoid CB1 receptor (A), cannabinoid CB2 receptor (B) 
in cell lysates from macrophages incubated or not with lipopolysaccharide (LPS, 1 µg/ml) for 18h. 
Cannabigerol (CBG, 1 µM) was added alone to the cell media or 30 min before LPS challenge. Data 
were analysed by GENEX software for group wise comparisons and statistical analysis. Results are 
means±SEM of four experiments. #p< 0.001 vs control. 
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4.1.2 CANNABICHROMENE (CBC) 
4.1.2.1 Effect of CBC on DNBS-induced colitis (colon weight/colon length ratio, intestinal 
permeability and myeloperoxidase activity) 
DNBS administration caused a significant increase in colon weight/colon length ratio (Figure 
15). CBC, at the doses of 0.1 and 1 mg/kg, (ip) after the inflammatory insult, significantly 
reduced the effects of DNBS on colon weight/colon length ratio. The effect was significant for 
the dose of 1 mg/kg. At the 1 mg/kg dose, CBC significantly reduced DNBS-induced increase 
in intestinal permeability (Figure 16A) and MPO activity (Figure 16B). 
4.1.2.2 Effect of CBC on histological damage and on immunohistochemical detection of 
Ki-67  
Histological analysis showed, in control mice, a normal appearance, with intact epithelium of 
the colonic mucosa (Figure 17A). In DNBS-treated mice, subtotal erosions of the mucosa, and 
diffuse lymphocyte infiltration involving the muscularis mucosae and the sub-mucosa were 
observed (Figure 17B). CBC treatment (1 mg/kg, given intraperitoneally after DNBS) resulted 
in a regenerative area surrounding the residual focal erosions (Figure 17C).   
Immunohistochemical analyses confirmed the beneficial effect of CBC on inflamed colonic 
mucosa. In control tissues, Ki-67 immunoreactivity revealed proliferative activity on the fundus 
of the foveole glands (Figure 18A).  In the colon from DNBS-treated mice, total necrosis with 
Ki-67 immunoreactivity on inflammatory cells was observed (Figure 18B). CBC (1 mg/kg, 
given intraperitoneally after DNBS) reduced the effect of DNBS on cell proliferation, the 
mitotic activity being restricted to one half of the mucosa (Figure 18C). 
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4.1.2.3 Cytotoxicity assay on murine peritoneal macrophages 
Cytotoxicity was evaluated performing the MTT assay and CBC, at the concentrations ranging 
from 0.001 to 1 µM, did not affect mitochondrial respiration (expressed as percentage of 
viability ± SEM) after 24-h exposure: [control 99.93 ± 4.70; CBC 0.001 µM 103.7 ± 8.0; CBC 
0.01 µM 101.3 ± 4.40; CBC 0.1 µM 96.29 ± 2.9; CBC 1 µM 103.8 ± 3.60; DMSO 20% v/v 
(used as positive control) 24.50 ± 1.78#; #p<0.001 vs control (n=3 experiments)]. Similarly the 
CB1 agonist ACEA (0.001-0.1 µM), the CB2 receptor agonist JWH133 (0.001-0.1 µM), the 
CB1 receptor antagonists rimonabant (0.1 µM) and AM251 (1 µM), the CB2 receptor antagonist 
SR144528 (0.1 µM) did not exert cytotoxic effects (data not shown) 
4.1.2.4 Nitrites measurements in murine peritoneal macrophages  
In cells not treated with LPS, CBC (0.001-1 µM) did not modify basal nitrite levels [nitrite 
levels (nM) ±SEM: control 614.4 ±31.5, CBC 0.001 µM 620.5±32.1, CBC 0.01 µM 
618.4±24.6, CBC 0.1µM 612.7±29.6, CBC 1µM 626.9±36.2; n=12]. LPS (1 µg/ml for 18 h) 
administration caused a significant increase in nitrite production (Figure 19). A pre-treatment 
with CBC (0.001-1 µM), 30 min before LPS, significantly reduced LPS-increased nitrite levels 
(Figure 19). CBC was also effective when given 15 hours after LPS challenge (i.e. three hours 
before nitrite assay) (see insert to Figure 19). No significant differences were found in CBC 
effect when the compound was given 30 min before LPS or 15 h after LPS (i.e. three hours 
before the nitrite assay, see overlapping curves in the insert to Figure 19).  Like CBC, the CB1 
agonist ACEA (0.001-0.1 µM) and the CB2 receptor agonist JWH133 (0.001-0.1 µM) reduced 
the production of nitrites stimulated by LPS when given 30 min before LPS [nitrite levels (nM) 
±SEM: control 642.2±51.6, LPS 1µg/ml 911.3±42.4#, ACEA 0.001µM 782.3±12.0*, ACEA 
0.01 µM 730.9±20.4**, ACEA 0.1 µM 699.8±18.1***; n=6, #p<0.01 vs control, *p<0.05, 
**p<0.01 and ***p<0.001 vs LPS alone. Control 842.0±18.4, LPS 1µg/ml 1200±55.3#, JWH133 
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0.001µM  942.5±70.7*, JWH133 0.01 µM 965.8±58.7*, JWH133 0.1 µM 707.0±83.6***; n=6, 
#p<0.001 vs control, *p<0.05 and ***p<0.001 vs LPS alone].  
4.1.2.5 Effect of CBC on iNOS and COX-2 (mRNA and protein) expression in LPS-
treated murine peritoneal macrophages 
In order to verify if the effect of CBC on the increased nitrite production was associated to 
changes in iNOS expression, we measured the mRNA and protein levels of this enzyme both 
by RT-PCR and by western blot. LPS administration up-regulated iNOS mRNA and protein 
expression (Figure 20A-C). CBC (1 µM) incubated 30 min before LPS stimulation, did not 
modify LPS-induced changes in iNOS expression (Figure 20A-C). Similarly to iNOS, LPS 
administration caused up-regulation of COX-2 mRNA and protein expression (Figure 20B-D). 
CBC (1 µM) incubated 30 min before LPS stimulation, did not modify LPS-induced COX-2 
up-regulation (Figure 20B-D). 
4.1.2.6 Effect of CBC on IL-1β, IL-10 and IFN-γ levels in LPS-treated murine peritoneal 
macrophages 
Interleukins and interferon-γ are important cytokines involved in LPS-evoked responses in 
macrophages. The levels of IL-1β, IFN-γ and IL-10 in macrophages medium were significantly 
increased after 18-h exposure to LPS (Figure 21A-C). A pre-treatment with CBC (1 µM), 
incubated 30 min before LPS stimulation, significantly reduced IL-10 and interferon-γ (but not 
IL-1β) levels in macrophages (Figure 21A-C). 
4.1.2.7 Effect of CBC in presence of selective CB1/CB2 receptor antagonists  
Because CBC can inhibit endocannabinoids inactivation (De Petrocellis et al., 2011), in this set 
of experiments we verified if CBC effect on nitrite production was reduced or counteracted by 
selective CB1 and CB2 receptor antagonists. We found that rimonabant (0.1 µM) (CB1
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antagonist) not only did not  counteract but, instead, significantly enhanced the inhibitory effect 
of CBC (1 µM) on nitrite production (Figure 22A). By contrast, the CB2 receptor antagonist SR 
144528, at a concentration (0.1 µM) able to block the effect of the selective CB2 receptor 
agonist JWH133 (0.1 µM) on nitrite production (data not shown) did not modify CBC (1 µM)-
induced changes in nitrite production (Figure 22B). Rimonabant and SR 144528, at the 
concentrations used, did not modify, per se, nitrite levels induced by LPS ([nitrite levels (nM) 
±SEM: control 611.9±27.4, LPS 1µg/ml 899.1±25.2#, rimonabant 0.1 µM  863.1±24.8, 
SR144528 0.1 µM 917.1±27.2; n=6, #p<0.001 vs control].  
Next, using [35S]GTPγS binding assays, we found that when tested at concentrations from 1 nM 
up to 1 µM, CBC did not display any significant ability to stimulate or inhibit [35S]GTPγS 
binding to hCB1-CHO cell membranes (data not shown). In contrast, using the same 
experimental conditions, we found that, when incubated by itself, 0.1 µM rimonabant induced, 
as expected, a marked inhibition of [35S]GTPγS binding in this bioassay. When 1 µM CBC was 
added 30 min after 0.1 µM rimonabant, no significant change in Emax of this inverse 
agonist/antagonist was observed (Figure 23).  
4.1.2.8 Effect of CBC on CB1, CB2 mRNA expression in murine peritoneal macrophages 
Results of the experiments measuring mRNA expression are shown in Figure 24 A-B. LPS (1 
µg/ml for 18 h) challenge caused up-regulation of CB1 receptors and down-regulation of CB2 
receptors. CBC did not modify CB1 and CB2 mRNA expression in LPS-treated macrophages 
(Figure 24 A-B).   
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4.1.2.9 Effect of CBC on endocannabinoids and related molecules in murine peritoneal 
macrophages 
Table 2 reports the levels of endocannabinoids, PEA and OEA in murine peritoneal 
macrophages treated with LPS. The exposure to LPS (1µg/ml) for 18 h induced a significant 
increase in anandamide (but not 2-AG, PEA or OEA) levels. CBC (1 µM) did not change the 
levels of the endocannabinoids and PEA in control macrophages (i.e. not treated with LPS), nor 
in macrophages challenged with LPS (Table 2). By contrast, CBC significantly increased OEA 
levels in LPS-treated macrophages (Table 2). 
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Figure 15. Dinitrobenzene sulfonic acid (DNBS)-induced colitis in mice. Colon weight/colon length 
ratio of colons from untreated and DNBS-treated mice in the presence or absence of cannabichromene 
(CBC). Tissues were analyzed 3 days after vehicle or DNBS (150 mg/kg, intracolonically) 
administration. CBC (0.1 and 1 mg/kg) was administered (ip) once a day for two consecutive days 
starting 24-h after the inflammatory insult. Bars are mean ± SEM of 12-15 mice for each experimental 
group. #p<0.001 vs control; **p<0.01 vs DNBS alone. 
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Figure 16. Inhibitory effect cannabichromene (CBC) on serum FICT-dextran concentration (a measure 
of intestinal barrier function) (A) and myeloperoxidase (MPO, a marker of intestinal inflammation) 
activity (B) in dinitrobenzene (DNBS)-induced colitis in mice. Permeability and MPO activity were 
measured on colonic tissues 3 days after vehicle or DNBS (150 mg/kg, intracolonically). CBC (1 
mg/kg) was administered (ip) for two consecutive days starting 24-h after the inflammatory insult. Bars 
are mean ± SEM of 5 mice for each experimental group. #p<0.001 vscontrol; *p<0.05 and **p<0.01 vs 
DNBS alone. 
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Figure 17. Histological evaluations of inflamed and non-inflamed colons: effect of cannabichromene 
(CBC). No histological modification was observed in the mucosa and sub-mucosa of control mice (A); 
mucosal injury induced by dinitrobenzene sulfonic acid (DNBS) administration (B); treatment with 
CBC reduced colon injury stimulating a regeneration of the glands (c). CBC (1 mg/kg) was 
administered (ip) for two consecutive days starting 24-h after the inflammatory insult. Histological 
analysis was performed 3 days after DNBS (150 mg/kg, intracolonically). Original magnification x200. 
The figure is representative of 3 experiments 
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Figure 18. Different patterns of Ki-67 immunoreactivity in the colonic mucosa of control mice (A), 
dinitrobenzene sulfonic acid (DNBS)-treated mice (B) and mice treated with DNBS plus 
cannabichromene (CBC) (C). (A) Ki-67 immunopositive cells localised to the lower of the crypts. (B) 
Ki-67 immunoreactivity  was observed on inflammatory cells. (C) Ki-67 immunopositive cells observed 
only in the expanded basal zone. CBC (1 mg/kg) was administered (ip) for two consecutive days 
starting 24-h after the inflammatory insult. The figure is representative of 3 experiments. 
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Figure 19. Inhibitory effect of cannabichromene on nitrite levels in the cell medium of murine 
peritoneal macrophages incubated with lipopolysaccharide (LPS, 1 µg/ml) for 18h. Cannabichromene 
(CBC, 0.001–1 µM) was added to the cell media 30 min before LPS challenge (i.e. 18.5 hours before 
nitrites assay). Results are mean±SEM of six experiments (in triplicates). #p<0.001 vs control; *p<0.05 
and ***p<0.001 vs LPS alone. The insert (on top of the figure) shows the effect of CBC (expressed as 
percentage of inhibition of the corresponding control values, with the difference between LPS and 
control considered as 100%) when given 30 min before LPS (CBC before LPS) or 15 hours after LPS 
(CBC after LPS). No statistically significant difference  was observed between the two concentration–
response curves reported in the insert.  
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Figure 20. Inducible nitric oxide synthase (iNOS) (A, B) and cyclooxygenase-2 (COX-2) (C, D) mRNA 
and protein levels in cell lysates from macrophages incubated or not with lipopolysaccharide (LPS, 1 
mg/mL) for 18 h. mRNA expression was evaluated by RT-PCR. The expression levels, normalized with 
respect to the reference genes, were scaled to the expression value of the control, considered as 1. The 
means of the quantitative-cycles (Cq) for the control were: 26.00 and 25.58 for iNOS and COX-2 
respectively. Protein expression was evaluated by Western blot analysis. Cannabichromene (CBC, 1 
µM) was added to the cell media 30 min before LPS challenge. #p< 0.001 versus control (n = 4–5 
experiments). 
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Figure 21. Effect of cannabichromene (CBC) on interleukin-1β (IL-1β) (A), interleukin-10 (IL-10) (B) 
and interferon-γ (C) levels detected in the cell media of macrophages incubated with lipopolysaccharide 
(LPS, 1 µg/ml) for 18h. CBC (1 µM) was added to the media 30 min before LPS challenge. Results are 
means±SEM of four experiments (in quadruplicates). #p<0.001 vs control, *p<0.05 and **p<0.01 vs LPS. 
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Figure 22. Effect of cannabichromene (CBC, 1 µM) alone or in presence of the cannabinoid CB1 
receptor antagonist rimonabant (0.1 µM) (A) as well as in the presence of the cannabinoid CB2 receptor 
antagonist SR144528 (0.1 µM) (B) on nitrite levels in the cell medium of murine peritoneal 
macrophages incubated with lipopolysaccharide (LPS, 1 µg/ml) for 18 h. The antagonists were added to 
the cell media 30 min before CBC exposure. LPS (1 µg/ml for 18 h) was incubated 30 min after CBC. 
Results are means±SEM of three experiments (in triplicates). #p<0.001 vs control; *p<0.05 and**p<0.01 
vs LPS; °p<0.05 vs LPS+CBC.  
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Figure 23. Effects of 1 µM cannabichromene alone (CBC), SR141716A alone (SR1, 0.1 µM; CB1 
receptor antagonist), and 1 µM CBC which was added 30 min after 0.1 µM SR141716A on [35S]GTPγS 
binding to hCB1- CHO cell membranes (n-12-16) (B). Symbols represent mean values ± SEM. 
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Figure 24. Relative mRNA expression of cannabinoid CB1 receptor (A) and cannabinoid CB2 receptor 
(B) in cell lysates from macrophages incubated or not with lipopolysaccharide (LPS, 1 µg/mL) for 18h: 
effect of cannabichromene (CBC, 1 µM, added to the cell media or 30 min before LPS challenge). The 
expression levels of mRNA, evaluated by RT-PCR and normalized with respect to the reference genes, 
was scaled for all conditions to the expression value of the control, considered as 1. The means of the 
quantitative-cycles (Cq) for the control values were: 31.2 (CB1 receptor)and 24.48 (CB2 receptor). The 
reaction background was 37.30 Cq and 36.60 Cq for CB1 receptor and CB2 receptor, respectively, at 40 
reaction cycles. #p< 0.001 vs control (n = 4). 
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Table 2. Anandamide (AEA), 2-arachydonylglycerol (2-AG), palmitoylethanolamide (PEA) 
and oleoylethanolamide (OEA) levels  in cell lysates from macrophages incubated or not with 
lipopolysaccharide (LPS, 1 µg/ml) for 18 h: effect of  cannabichromene (CBC, 1 µM, added 
alone to the cell media or 30 min before LPS challenge). 
 
 
 
Results (pmol/mg lipid) are mean±SEM of 3-6 experiments. #p<0.01 vs control; *p<0.05 vs 
LPS 
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4.1.3 ∆9-TETRAHYDROCANNABIVARIN (THCV) 
4.1.3.1  Effect of THCV on DNBS-induced colitis (colon weight/colon length ratio) 
DNBS administration caused a significant increase in colon weight/colon length ratio (Figure 
25). THCV (0.3-5 mg/kg, intraperitoneally), at the dose of 1 mg/kg (given after the 
inflammatory insult), significantly reduced the effects of DNBS on colon weight/colon length 
ratio (Figure 25). 
4.1.3.2 Effect of THCV on murine peritoneal macrophages viability 
Cytotoxicity was evaluated performing the MTT assay and THCV, at the concentrations 
ranging from 0.001 to 1 µM, did not affect mitochondrial respiration (expressed as percentage 
of viability ± SEM) after 24-h exposure: [control 99.98 ± 4.58; THCV 0.001 µM 111.30 ± 
3.87; THCV 0.01 µM 104.7 ± 6.45; THCV 0.1 µM 105.6 ± 6.18; THCV 1 µM 112.60 ± 6.88; 
THCV 10 µM 17.16 ± 1.62#; #p<0.001 vs control (n=3 experiments)]. Similarly, the CB1 
receptor antagonists rimonabant (0.1 µM) and the CB2 receptor antagonist SR 144528 (0.1 µM) 
did not exert cytotoxic effects (data not shown).  
4.1.3.3 Effect of THCV on nitrite levels in murine peritoneal macrophages 
In cells not treated with LPS, THCV (1 µM) did not modify per se basal nitrite levels [nitrite 
levels (nM)±SEM: control 653.2±38.79, THCV 1µM 669.6±47.53; n=18]. LPS (1 µg/ml for 18 
h) administration caused a significant increase in nitrite production (Figure 26). A pre-
treatment with THCV (0.001-1 µM, both), 30 minutes before LPS, significantly reduced LPS-
increased nitrite levels (Figure 26).  
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4.1.3.4 Effect of THCV on nitrite production in murine peritoneal macrophages in 
presence of selective cannabinoid receptors antagonists  
Since some phytocannabinoids may exert pharmacological action via direct or indirect 
activation of cannabinoid receptors (Izzo et al., 2009), in this set of experiments we verified if 
THCV effects on nitrite production was reduced or counteracted by selective CB1 and CB2 
receptor antagonists. We observed that rimonabant (0.1 µM, CB1 receptor antagonist) did not 
modify THCV (1 µM)-induced changes in nitrite production (Figure 27A). On the other hand, 
selective cannabinoid CB2 receptor antagonists (SR 144528 0.1 µM) counteracted the effect of 
THCV on nitrite levels in LPS-stimulated macrophages (Figure 27B). The cannabinoid receptor 
antagonists employed in this set of experiments, at the concentrations used, did not affect, per 
se, nitrite levels induced by LPS (data not shown). 
4.1.3.5 Effect of THCV on iNOS and COX-2 protein expression in LPS-treated 
macrophages 
In order to verify if the effect of THCV on nitrite production in LPS-treated peritoneal 
macrophages was associated to changes in iNOS expression, we measured, by western blot, the 
protein levels of this enzyme. LPS administration caused an up-regulation on iNOS and COX-2 
protein expression (Figure 28A-B). THCV (1 µM concentration), incubated 30 min before LPS 
stimulation, significantly reduced the LPS-induced changes in iNOS and COX-2 expression 
(Figure 28A-B).  
4.1.3.6 Effect of THCV on IL-1β levels in LPS-treated murine peritoneal macrophages 
Interleukins are important cytokines involved in LPS-evoked responses in macrophages and IL-
1β represents one of the main pro-inflammatory cytokines able to induce COX-2 expression in 
macrophages. The level of IL-1β in macrophages medium was significantly increased after 18-
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h exposure to LPS (Figure 29). A pre-treatment with THCV (1 µM), incubated 30 min before 
LPS stimulation, significantly reduced IL-1β level in LPS-stimulated macrophages  (Figure 
29). 
4.1.3.7 Effect of THCV on cannabinoid receptors mRNA expression in LPS-treated 
macrophages  
LPS up-regulated CB1 receptors and down-regulated CB2 receptor mRNA expression in 
macrophages (Figure 30A-B). THCV did not affect cannabinoid CB1 and CB2 mRNA 
expression in un-stimulated macrophages, but it was able to reduce significantly the up-
regulation of CB1 mRNA expression induced in macrophages by LPS (Figure 30A). 
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Figure 25. Dinitrobenzene sulfonic acid (DNBS)-induced colitis in mice. Colon weight/colon length 
ratio of colons from untreated and DNBS-treated mice in the presence or absence of ∆9-
tetrahydrocannabivarin (THCV). Tissues were analyzed 3 days after vehicle or DNBS (150 mg/kg, 
intracolonically) administration. THCV (0.3-5 mg/kg) was administered (ip) once a day for two 
consecutive days starting 24-h after the inflammatory insult. Bars are mean ± SEM of 12-15 mice for 
each experimental group. #p<0.001 vs control; **p<0.01 vs DNBS alone. 
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Figure 26. Inhibitory effect of ∆9-tetrahydrocannabivarin (THCV) on nitrite levels in the cell medium 
of murine peritoneal macrophages incubated with lipopolysaccharide (LPS, 1 µg/ml) for 18 h. THCV 
(0.001-1 µM) was added to the cell media 30 min before LPS stimulus (i.e. 18.5 hours before nitrites 
assay). Results are mean±SEM of three experiments (in triplicates). #p<0.001 vs control; *p<0.05 and 
**p<0.01vs LPS alone.  
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Figure 27. Effect of ∆9-tetrahydrocannabivarin (THCV, 1 µM) alone or in presence of the cannabinoid 
CB1 receptor antagonist rimonabant (0.1 µM) (A) and of the cannabinoid CB2 receptor antagonist 
SR144528 (0.1 µM) (B) on nitrite levels in the cell medium of murine peritoneal macrophages 
incubated with lipopolysaccharide (LPS, 1 µg/ml) for 18 h. The antagonists were added to the cell 
media 30 min before THCV exposure. LPS (1 µg/ml for 18 h) was incubated 30 min after THCV. 
Results are means±SEM of three experiments (in triplicates). #p<0.001 vs control; ***p<0.001 vs LPS; 
°p<0.001vs LPS+THCV.  
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Figure 28. Inducible nitric oxide synthase (iNOS) (A) and cyclooxygenase-2 (COX-2) (B) protein 
levels in cell lysates from macrophages incubated or not with lipopolysaccharide (LPS, 1 µg/mL) for 18 
h evaluated by Western blot analysis. ∆9-tetrahydrocannabivarin (THCV, 1 µM) was added to the cell 
media 30 min before LPS challenge. #p< 0.001 vs control; ***p< 0.001 vs control (n = 4–5 experiments). 
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Figure 29. Effect of ∆9-tetrahydrocannabivarin (THCV) on interleukin-1β (IL-1β) levels detected in the 
cell media of macrophages incubated with lipopolysaccharide (LPS, 1 µg/ml) for 18h. THCV (1 µM) 
was added to the media 30 min before LPS challenge. Results are means±SEM of three experiments 
**p<0.01 vs control, *p<0.05 vs LPS. 
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Figure 30. Relative mRNA expression of cannabinoid CB1 receptor (A), cannabinoid CB2receptor (B) 
in cell lysates from macrophages incubated or not with lipopolysaccharide (LPS, 1 µg/ml) for 18h. ∆9-
tetrahydrocannabivarin (THCV, 1 µM) was added alone to the cell media or 30 min before LPS 
challenge. Data were analysed by GENEX software for group comparisons and statistical analysis. 
Results are means±SEM of four experiments. #p< 0.001 vs control; **p< 0.01 vs LPS. 
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4.2 COLON CANCER 
4.2.1 CANNABIDIOL (CBD) AND CANNABIS-EXTRACT WITH HIGH CONTENT IN 
CANNABIDIOL (CBD BDS)  
4.2.1.1  Effect of CBD and CBD BDS on the formation of aberrant crypt foci (ACF), 
polyps and tumors  
The carcinogenic agent AOM given alone induced the expected appearance of ACF (Figure 
31B), polyps (Figure 31C) and tumours (Figure 31D) after 3 months of treatment. CBD (1 
mg/kg, ip) significantly reduced AOM-induced ACF (67% inhibition) (Figure 31B), polyps 
(57% inhibition) (Figure 31C) and tumours (66% inhibition) (Figure 31D). CBD (5 mg/kg, ip) 
significantly reduced only the formation of polyps (Figure 31C). The Cannabis-extract with 
high content in cannabidiol, here named CBD BDS, at the dose of 5 mg/kg (ip), significantly 
reduced AOM-induced ACF (86% inhibition) and polyps (79% inhibition). CBD BDS also 
reduced tumour formation by 40%, although a conventional statistical significance was not 
fully achieved (Figure 32B-D).   
4.2.1.2 Effect of CBD and CBD BDS in xenograft colorectal tumours in mice 
To assess the potential curative effect of CBD and CBD BDS on colorectal cancer, athymic 
nude mice bearing colorectal tumor xenografts were treated daily with CBD and CBD BDS 
(both at 5 mg/kg dose, ip). CBD was able to reduce tumour volume comparison to the control 
mice (mice not receiving any treatment) (Figure 31A). On the other hand, the average tumour 
volume in mice treated with CBD BDS was significantly lower compared with vehicle-treated 
control mice (Figure 32A). For example, 4 days after the commencement of CBD BDS 
challenge, the average tumor volume in control mice (mean±SEM: 1130±171.6mm3) was 
approximately 1.5 fold higher as compared to mice treated with 5 mg/kg CBD BDS 
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(mean±SEM: 755±124 mm3). However, no differences in tumour growth were observed after 
7-days CBD BDS treatment.  
4.2.1.3 Effect of CBD on COX-2, iNOS, phospho-Akt and caspase-3 protein expression in 
colonic tissues 
Western blot analysis revealed protein expression of COX-2, iNOS, phospho-Akt and caspase-
3 (Figure 33A-D) in colonic tissues of both healthy and AOM-treated animals. The 
densitometric analysis indicated a significant increase in the expression of COX-2 (Figure 
33A), iNOS (Figure 33B) and phospho-Akt (Figure 33C) in the colons of AOM-treated mice. 
CBD (1 mg/kg) did not cause significant changes in the expression of COX-2 and iNOS in 
AOM-treated animals (Figure 33A-B) but significantly reduced AOM-induced Akt protein 
phosphorylation (Figure 33C). AOM treatment caused a significant down-regulation of cleaved 
caspase-3 expression, which was restored by cannabidiol (Figure 33D). 
4.2.1.4 Effect of CBD and CBD BDS on cell viability  
The effect of CBD and CBD BDS on cell viability was evaluated in human colorectal cancer 
cell lines such as Caco-2, HCT116 and DLD-1cells as well as in human healthy colonic 
epithelial cell line (HCEC) by using the neutral red assay. CBD, at the concentration ranging 
from 0.01 to 10 µM, and CBD BDS, at the concentration ranging from 1 to 5 µM, did not affect 
both colorectal cancer and healthy cells viability (expressed as percentage of viability ± SEM) 
after 24-h exposure: [Caco-2 cells: control 100.2 ± 6.1; CBD 0.01 µM: 98.0 ± 8.6; CBD 0.1 
µM: 100.5 ± 2.0; CBD 1 µM: 97.0 ± 2.47; CBD 10 µM: 99.25 ± 4.5; HCT 116 cells: control 
100.1 ± 2.5; CBD 0.01 µM: 105.3 ± 2.5; CBD 0.1 µM: 102.0 ± 5.5; CBD 1 µM: 101.7 ± 2.5; 
CBD 10 µM: 106.1 ± 1.7; control 100 ± 7.05; CBD 1 µM: 111.4 ± 6.56; CBD 3 µM: 116.3 ± 
6.49; CBD 5 µM: 110.4 ± 4.30; CBD BDS 1 µM: 108.3 ± 5.11; CBD BDS 3 µM: 107 ± 4.75; 
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CBD BDS 5 µM: 105.5 ± 5.44; DLD-1 cells: control 100 ± 5.84; CBD BDS 1 µM: 106 ± 4; 
CBD BDS 3 µM: 103 ± 3.3; CBD BDS 5 µM: 99.6 ± 3.7; CBD 1 µM: 106.0 ± 5.4; CBD 3 µM: 
102.8 ± 6.99; CBD 5 µM: 102.9 ± 5.18; HCEC cells: control 100 ± 7.05; CBD BDS 1 µM: 
86.74 ± 4.8; CBD BDS 3 µM: 95.19 ± 5.93; CBD BDS 5 µM: 92.81 ± 4.08; CBD 1 µM: 101.6 
± 4.99; CBD 3 µM: 101.6 ± 4.99; CBD 5 µM: 97.03 ± 5.66) (n=3 experiments for each cell 
line). DMSO (20% v/v), used as positive control, significantly reduced both colorectal cancer 
and healthy cells viability (data not shown).  
4.2.1.5 Effect of CBD and CBD BDS on healthy colonic epithelial cells (HCEC) 
proliferation 
In order to verify if the effect of Cannabis-based products was specific for cancer cells, we 
investigated the effect of both CBD and CBD BDS on proliferation in HCEC. Both CBD and 
CBD BDS, up to 5 µM, did not affect significantly proliferation in HCEC (Figure 34A-B). 
Spermine (300 µM), used as a positive control, significantly reduce HCEC proliferation (Figure 
34A-B). 
4.2.1.6 Effect of CBD and CBD BDS on human colon adenocarcinoma cells proliferation 
The effect of non-cytotoxic concentrations of CBD (0.01–10 µM) was evaluated on cell 
proliferation in Caco-2 (Figure 35A), HCT 116 (Figure 35 C and Figure 36 C) and DLD-1 
(Figure 36 A) cells by MTT assay  and 3H-thymidine incorporation (only for Caco-2 cells and 
HCT 116) (Figure 35B and Figure 35D respectively). In the cell lines tested CBD, with both 
techniques, exerted a significant antiproliferative effect. The effect of non-cytotoxic 
concentrations of CBD BDS (0.3–5 µM) was evaluated on cell proliferation in both DLD-1 
(Figure 36B) and HCT116 cells (Figure 36D) using the MTT assay in which it showed a 
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significant antiproliferative effect. No difference in potency and efficacy were observed 
between CBD and CBD BDS (see inserts on top of figure 36).  
4.2.1.7 Effect of CBD and CBD BDS on colorectal cancer cell proliferation in presence of 
selective receptor antagonists 
Using the MTT assay, we found that the effect of cannabidiol (CBD, 10 µM) on Caco-2 cell 
proliferation was counteracted by rimonabant (0.1 µM) and AM251 (1 µM) (two CB1 receptor 
antagonists), capsazepine (1 µM, a TRPV1 receptor antagonist) and GW9662 (10 µM, a 
PPARγ receptor antagonist) (Figure 37A-B-E-F). By contrast, the effect of CBD was not 
significantly changed by SR144528 (10 µM) and AM630 (1 µM) (CB2 receptor antagonists) 
(Figure 37C-D). In other set of experiments we investigated the effect of CBD and CBD BDS 
on DLD-1 cell proliferation in the presence of selective cannabinoid CB1 and CB2 receptor 
antagonists. We found that selective cannabinoid CB1 receptor antagonists (i.e. rimonabant 0.1 
µM and AM251 1µM) counteracted the effect of both CBD and CBD BDS (both at 3 µM 
concentration) on cell proliferation (Figure 38A-D). On the other hand, selective cannabinoid 
CB2 receptor antagonists (i.e. SR144528 0.1 µM and AM630 1 µM) counteracted the effect of 
CBD BDS (3 µM), but not the effect of pure CBD (3 µM), on cell proliferation (Figure 39A-
D). All receptor antagonists employed in this set of experiments were not cytotoxic and did not 
affect, per se, cell proliferation (data not shown). 
4.2.1.8 CBD and CBD BDS: binding profiles on cannabinoid receptors 
Because selective CB1 and CB2 receptor antagonists differently affected the response to CBD 
and CBD BDS in DLD-1 cell line, we performed displacement binding assays to compare the 
cannabinoid binding profiles of CBD to CBD BDS. CBD BDS showed greater affinity for 
cannabinoid receptors than pure CBD in both hCB1-CHO and hCB2-CHO cell membranes 
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(Figure 40A-B). The CBD BDS Ki values for CB1 and CB2 receptors were 0.18 µM and 0.14 
µM, respectively; pure CBD only (and partially) displaced [3H]CP55940 at the highest 
concentration tested (10 µM) (Figure 40A-B). 
4.2.1.9 Effect of CBD on endocannabinoids, palmitoylethanolamide and 
oleoylethanolamide levels in Caco-2 cells 
The exposure to CBD (0.1–10 µM) for 24 h induced an increase in 2-AG levels (Figure 41B) in 
sub-confluent Caco-2 cells. The effect was significant for the 0.1 µM concentration. No 
significant differences were observed in anandamide, palmitoylethanolamide and 
oleoylethanolamide levels following CBD (0.1–10 µM) incubation for 24 h (Figure 41A-C-D). 
4.2.1.10 Effect of CBD on genotoxicity in Caco-2 cells 
Compared to the control cells (A), CBD (10 µM) alone did not significantly affect DNA 
damage after 24-h exposure (C), suggesting the absence of a genotoxic effect (Figure 42). 
Exposure of Caco-2 cells to hydrogen peroxide H2O2 (75 µM) produced a significant increase 
in the percentage of DNA in comet tails (B), whereas a pre-treatment with CBD (10 µM) (D) 
for 24 h significantly reduced the H2O2-induced DNA damage (Figure 42). 
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Figure 31. Cannabidiol (CBD, 1-5 mg/kg, ip) reduces colon carcinogenesis in vivo. Figure 31A reports 
the inhibitory effect of CBD (5 mg/kg, ip) on xenograft formation induced by subcutaneous injection of 
HCT 116 cells into the right flank of athymic female mice. Treatment started approximately after 10 
days of cell inoculation. Tumour size was measured every day by digital caliper measurements, and 
tumour volume was calculated. CBD (5 mg/kg, ip) was given every day for the whole duration of the 
experiment. Figure 31B-D reports the inhibitory effect of CBD (1-5 mg/kg, ip) on aberrant crypt foci 
with four or more crypts (ACF≥4/mouse) (B), polyps (C) and tumours (D) induced in the mouse colon 
by azoxymethane (AOM). CBD was given ip three times a week for the whole duration of the 
experiment starting 1 week before the first administration of AOM. Measurements were performed 3 
months after the first injection of AOM. Each point for xenograft curve represents the mean ± SEM of 8 
animals for each experimental group. ***p<0.001; ANOVA CBD curve vs control curve. For AOM 
model, each bar represents bar represents the mean±SE mean of 9–11 mice. *p<0.05 and **p<0.01 vs 
vehicle 
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Figure 32. A Cannabis sativa extract with high content of CBD (CBD BDS, 5 mg/kg, ip) reduces colon 
carcinogenesis in vivo. Figure 32A reports the inhibitory effect of Cannabis sativa extract with high 
content of CBD (CBD BDS, 5 mg/kg, ip) on xenograft formation induced by subcutaneous injection of 
HCT 116 cells into the right flank of athymic female mice. Approximately treatment started after 10 
days of cell inoculation. Tumour size was measured every day by digital caliper measurements, and 
tumour volume was calculated. CBD BDS (5 mg/kg, ip) was given every day for the whole duration of 
the experiment. Figure 32B-D report the inhibitory effect of CBD BDS (5 mg/kg, ip) on aberrant crypt 
foci with four or more crypts (ACF≥4/mouse) (B), polyps (C) and tumours (D) induced in the mouse 
colon by azoxymethane (AOM). CBD BDS was given ip three times a week for the whole duration of 
the experiment starting 1 week before the first administration of AOM. Measurements were performed 3 
months after the first injection of AOM. Each point for xenograft curve represents the mean ± SEM of 8 
animals for each experimental group. *p<0.05; ANOVA CBD BDS curve vs control curve. For AOM 
model, each bar represents the mean±SEM of 9–11 mice. **p<0.01 and ***p<0.001 vs AOM. 
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Figure 33. Cyclooxygenase-2 (COX-2) (A), inducible nitric oxide synthase(iNOS) (B), phospho-Akt 
(C) and cleaved caspase-3 (active fragmentp17) (D) expression in colonic tissues of mice treated or not 
with AOM:effect of cannabidiol (CBD, 1 mg/kgip). Each bar represents themean±SE mean of four/five 
independent experiments. *p<0.05 and#p<0.001vscontrol;**p<0.01 and °p<0.001vs AOM. 
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Figure 34. Effect of cannabidiol(CBD, 1–5 µM, 24-h exposure) and a Cannabis sativa extract with high 
content  of  CBD (CBD BDS, 1-5 µM) on cell proliferation in healthy human colonic epithelial cells 
(HCEC). Proliferation rate was studied using the MTT assay. Each bar represents the mean±SEM of 
two independent experiments. Spermine (300 µM) was used as a positive control. ***p<0.001 vs control. 
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Figure 35. Antiproliferative effects of cannabidiol (CBD, 0.01–10 µM, 24h exposure) in Caco-2 (A, B) 
and HCT116 (C, D) cells. Proliferation rate was studied using two different techniques: the MTT assay 
(A, C) and the 3H-thymidine incorporation (B, C). Each bar represents the mean±SE mean of three 
independent experiments. *p<0.05, **p<0.01 and ***p<0.001 vs control. 
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Figure 36. Antiproliferative effects of cannabidiol (CBD, 0.3–5 µM, 24-h exposure) and a Cannabis 
sativa extract with high content  of  CBD (CBD BDS, 0.3–5 µM, 24-h exposure) in DLD-1 (A-B) and 
HCT 116 cells (C-D). Proliferation (expressed as percentage of cell proliferation) rate was studied using 
the MTT assay. Each bar represents the mean±SEM of three independent experiments. *p<0.05, 
**p<0.01 and ***p<0.001 vs control. The inserts (on top of the figures) show the effect of CBD and CBD 
BDS (expressed as percentage of cell proliferation inhibition). No statistically significant difference was 
observed between the cannabinoids response curves reported in the inserts. 
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Figure 37. Antiproliferative effects, evaluated by MTT assay, of cannabidiol (CBD, 10µM, 24 h-
exposure) alone or in the presence of rimonabant (RIM, 0.1 µM, A) and AM251 (1 µM, B) (two 
selective CB1 receptor antagonists), SR144528 (10 µM, C) and AM630 (1 µM, D) (two selective CB2 
receptor antagonists), capsazepine (1 µM, E) (a TRPV1 antagonist) and GW9662 (10 µM) (a PPARγ 
antagonist, F). The antagonists were incubated 30 min before CBD. Each bar represents the mean±SE 
mean of three independent experiments. *p<0.05, **p<0.01 and ***p<0.001 vs control; °p<0.05 and 
°°p<0.01 vs CBD. 
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Figure 38. Antiproliferative effect, evaluated by MTT assay, of cannabidiol (CBD) and a Cannabis 
sativa extract with high content of CBD (CBD BDS, both at 3 µM, 24 h-exposure) alone or in the 
presence of one or other of two selective cannabinoid CB1 receptor antagonists, i.e. rimonabant (RIM, 
0.1 µM) and AM251 (1 µM). The antagonists were incubated 30 min before cannabinoid drugs. Each 
bar represents the mean±SEM of two independent experiments. **p<0.01 and ***p<0.001 vs control; 
#p<0.001 vs CBD (or CBD BDS). 
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Figure 39. Antiproliferative effect, evaluated by MTT assay, of cannabidiol (CBD) and a Cannabis 
sativa extract with high content  of  CBD (CBD BDS, both at 3 µM, 24 h-exposure) alone or in 
presence of one or other of two selective cannabinoid CB2 receptor antagonists, i.e. SR144528 
(SR2, 0.1 µM) and AM630 (1 µM). The antagonists were incubated 30 min before cannabinoid 
drugs. Each bar represents the mean±SEM of two independent experiments. ***p<0.001 vs control; 
#p<0.001 vs CBD (or CBD BDS). 
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Figure 40. Displacement of [3H]CP55940 by cannabidiol (CBD) and a Cannabis sativa extract 
with high content of CBD (CBD BDS) from specific binding sites on hCB1-CHO cell membranes 
(A) and hCB2-CHO cell membranes (B). Each symbol represents the mean percent displacement ± 
SEM (n=4). 
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Figure 41. Levels of anandamide (A), 2-arachidonoylglycerol (2-AG, B),palmitoylethanolamide 
(PEA, C) and oleoylethanolamide (OEA, D) in Caco-2 cells exposed to cannabidiol (CBD, 0.1–10 
µM, 24 h). Each bar represents the mean±SE mean of three independent experiments.*p<0.05 vs 
control. 
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Figure 42. Effect of cannabidiol (CBD, 10 µM for 24 h) on hydrogenperoxide (H2O2)-induced DNA 
damage evaluated by the comet assay. The DNA damage was induced in Caco-2 cells by 75 µMH2O2 
(B) and compared with PBS-treated (undamaged) cells (A). The effect of CBDwas studied in presence 
(D) or absence (C) ofH2O2. A–D Representative comets. Each bar represents the mean±SE mean of 
three independent experiments where at least 75 cells per gel in triplicate were scored. #p<0.001 vs 
undamaged cells (A, PBS) and ***p<0.001 vs damaged cells (B, H2O2). DNA damage, expressed as 
percentage of fluorescencein the comet tail (% DNA tail) was quantified using at least 75cells per gel 
were scored and each sample was evaluated in triplicate (n= independent experiments). 
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4.2.2 CANNABIGEROL (CBG) 
4.2.2.1 Effect of CBG in azoxymethane (AOM) murine model of colon cancer  
AOM treatment resulted in the formation of ACF, polyps and tumours (Figure 43B-D). Only 
foci with 4 or more crypts were analysed since it has been suggested that ACF (containing four 
or more crypts per focus) have higher risk for malignant tumor progression. Compared with the 
control group with AOM, CBG (1 and 5 mg/kg)-treated animals showed a reduced number of 
ACF (Figure 43B). Notably, at the 5 mg/kg dose, CBG completely suppressed the formation of 
ACF. CBG did not affect significantly polyp formation, but, at least at the 5 mg/kg dose, it 
reduced by one half the number of tumours  (Figure 43C-D). 
4.2.2.2 Effect of CBG in xenograft colorectal tumours mice model  
We determined the potential in vivo antitumoural curative effect of CBG by inoculating 
subcutaneously colorectal cancer cells in athymic nude mice. Following intraperitoneal 
injection with CBG (1-10 mg/kg), a marked inhibition of the growth of the xenografted 
tumours was observed, the effect being significant for the 3 mg/kg and 10 mg/kg doses (Figure 
43A). The differences in tumour volumes between the vehicle and the 3 mg/kg and 10 mg/kg 
CBG treatment groups were statistically significant from day 3th of treatment to the end of the 
experiment. After 5 days of drug administration, the average tumour volume in the control 
group was 2500±414 mm3, whereas the average tumour volume in the 3 mg/kg CBG-treated 
group was 1367±243, exhibiting a 45.3 % inhibition of tumour growth (Figure 43A).  
4.2.2.3 CB1, CB2, TRPA1, TRPV1, TRPV2, TRPM8 and 5-HT1A mRNA expression in 
colorectal carcinoma (Caco-2) cells and healthy human colonic epithelial cells (HCEC)  
CBG has been shown to behave as a weak partial agonist at CB1 and CB2 receptors, a relatively 
potent and highly effective TRPA1 agonist, a weak agonist at TRPV1 and TRPV2, and a potent 
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TRPM8 and 5-HT1A receptor antagonist. Thus, we analysed, by RT-PCR, the possible presence 
of such potential targets in Caco-2 cells as well as in HCEC. Results showed that all the 
investigated targets are expressed in Caco-2 cells, with TRPV1, CB2, 5HT1A more expressed 
than CB1, TRPM8, TRPV2 and TRPA1 (Table 3). In HCEC, the rank order of expression was 
TRPV1>> CB1, TRPA1 and TRPV2, with TRPM8, CB2, 5HT1A receptors very faintly 
expressed (expression values very close to background values) (Table 3). 
4.2.2.4 Effect of CBG on colorectal cancer (Caco-2) cells viability  
Because the effect of pCBs on tumoural cells viability is known to be increased with a low 
serum proteins concentration (De Petrocellis et al., 2013), in the first series of experiments we 
evaluated the effect of CBG in Caco-2 cells incubated (3-48 hours) with 1% FBS.  By using the 
MTT assay we found that CBG, in the presence of 1% FBS, three hours after its incubation, 
exerted a significant cytotoxic effect only at the highest concentration tested (30 µM), while 
after 48 h a significant inhibitory effect was achieved starting from the 3 µM concentration 
(Figure 44). A maximal inhibitory effect was achieved after 24-48 hours incubation 
[IC50±SEM:  3.8±2.1 µM (24 h incubation); 1.3±2.2 µM (48 h incubation]. Further experiments 
were performed at the 24 h because at this time point: i)  CBG displayed  a well-defined 
concentration-related effect and ii) CBG displayed a submaximal IC50 value. 
4.2.2.5 Effect of CBG on colorectal cancer HCT 116 and on healthy human colonic 
epithelial (HCEC) cells viability 
Figure 45A shows that CBG also reduced viability in another colorectal cancer (i.e. HCT116) 
cell line, with a significant inhibitory effect starting from the 3 µM concentration. To 
investigate the selectivity of CBG effect in tumoral vs non-tumoral cells, various concentrations 
(from 1-30 µM) of CBG were tested in HCEC. CBG, at a concentration similar to its IC50 
105 
 
values in colorectal cancer cells (3.8±2.1 µM), did not affect the vitality of HCEC (Figure 
45B). Only at a concentration of 30 µM (i.e. a concentration that was 7.8 fold higher than the 
IC50 value), CBG exhibited a cytotoxic effect in these non-tumoral cells. 
4.2.2.6 Effect of CBG on colorectal cancer (Caco-2) cells viability in presence of 
cannabinoids receptor antagonists  
Since CBG is a constituent of Cannabis, we verified if its effect on cell viability on Caco-2 
cells was affected by selective CB1 and CB2 receptor antagonists. We found that the CB1 
receptor antagonist AM251 did not modify CBG (10 µM)-induced changes in cell viability 
(Figure 46A). By contrast, the CB2 receptor antagonist AM630 (1 µM) not only did not 
counteract but, instead, significantly enhanced the inhibitory effect of CBG (1 µM) on cell 
viability (Figure 46A).  
4.2.2.7 Effect of CBG on colorectal cancer (Caco-2) cells viability in presence of a TRP 
channel antagonist 
Ruthenium red is a non-selective TRP channel antagonists. Specifically, it blocks TRPA1 
(IC50< 1-3 µM), TRPV1 (IC50: 0.09-0.22 µM) and TRPV2 (IC50: 0.6 µM), being the TRPM8 
insensitive to its action (Alexander et al., 2013). We found that ruthenium red, at 
concentrations (10 µM and 25 µM) several fold higher than the IC50 able to block TRPA1, 
TRPV1 and TRPV2 channels (Alexander et al., 2013), did not modify significantly the 
inhibitory effect of CBG on cell viability (Figure 46B).  
4.2.2.8 Effect of TRPM8 antagonists on colorectal cancer (Caco-2) cells viability  
Because CBG is a potent TRPM8 antagonist (De Petrocellis et al., 2011) in this series of 
experiments we verified if the effect of CBG was shared by well-established TRPM8 
antagonists. We found that, similarly to CBG, the synthetic TRPM8 antagonist AMTB as well 
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as cannabidiol and cannabidivarin (two Cannabis-derived TRPM8 antagonists) inhibited, in a 
concentration-dependent manner, Caco-2 cells viability (Figure 47A-C). Cannabichromene, 
another phytocannabinoid without activity at the TRPM8 channel (De Petrocellis et al., 2011), 
inhibited cell growth only at the highest concentration (30 µM) tested (Figure 47D). 
4.2.2.9 Effect of a 5HT1A antagonist on colorectal (Caco-2) cells viability  
CBG is a moderately potent 5-HT1A antagonist (Cascio et al., 2010). In contrast to TRPM8 
antagonists, the effect of CBG was not mimicked by the 5-HT1A antagonist WAY100635 (up to 
1 µM) (cell viability %: control 100±6.3; WAY100635 0.2 µM 97.2 ±6.2; WAY100635 1 µM 
95.9±6.2; DMSO 20 % 47.9±3.8*; *p<0.001 vs control, n=3 experiments including 8–10 
replicates for each treatment), thus suggesting the lack of involvement of such receptor. 
4.2.2.10 Effect of CBG on apoptosis and necrosis  
To investigate whether the growth inhibitory effect of CBG was due to induction of apoptosis 
or necrosis, we examined Caco-2 cell death by eosin-haematoxylin staining.  As shown in 
Figure 48A, compared to necrotic cells, the number of apoptotic cells was elevated after CBG 
treatment (CBG 10 µM: 72±11.0 % of apoptotic cells; 17.7±7.2 % of necrotic cells; n=3). 
Morphological assessment revealed absence of death in untreated cells  and the presence of 
cells with a typical apoptotic morphology (i.e. reduced size, hypereosinophilic cytoplasm, 
hyperchromic nucleus, irregular nuclear membrane and nuclear material outside the nucleus) in 
cells incubated with  CBG. The induction of apoptosis by CBG was confirmed by enzymatic 
assay, which indicated a 2.43 fold increase of caspase 3/7 activity  in CBG treated Caco-2 cells 
compared to vehicle (Figure 48B). 
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4.2.2.11 Effect of CBG on reactive oxygen species (ROS) production in colorectal (Caco-2) 
and in healthy human colonic epithelial (HCEC) cells 
To determine if the apoptotic action of CBG was associated to ROS production, we measured 
the levels of ROS generation by using the fluorescence sensitive probe DCFH-DA. We found 
that CBG 10 µM significantly increased ROS production in Caco-2 cells (Figure 49A) but not 
in HCEC (Figure 49B). Fenton's reagent (2 mM of H2O2/Fe+2), used as a positive control, 
increased ROS production both in Caco-2 cells and in HCEC (data not shown). 
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Figure 43. CBG reduces colon carcinogenesis in vivo. Figure 43A reports the inhibitory effect of 
cannabigerol (CBG, 1-10 mg/kg) on xenograft formation induced by subcutaneous injection of HCT 
116 cells into the right flank of athymic female mice. Approximately, treatment started after 10 days of 
cell inoculation. Tumour size was measured every day by digital caliper measurements, and tumour 
volume was calculated. CBG (1-10 mg/kg, ip) was given every day for the whole duration of the 
experiment. Figure 43B-D report the inhibitory effect of CBG (1 and 5 mg/kg) on aberrant crypt foci 
with four or more crypts (ACF≥4/mouse) (B), polyps (C) and tumours (D) induced in the mouse colon 
by azoxymethane (AOM). CBG was given ip three times a week for the whole duration of the 
experiment starting 1 week before the first administration of AOM. Measurements were performed 3 
months after the first injection of AOM.Each point for xenograft curve represents the mean ± SEM of 8 
animals for each experimental group. #p<0.001; ANOVA CBG curves vs control curve. For AOM 
model, each bar represents the mean ± SEM of 9-11 mice. p<0.058 and ***p<0.001 vs AOM alone.  
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Table 3: Detection of CB1, CB2, TRPA1, TRPV1, TRPV2, TRPM8 and 5-HT1A 
mRNA by quantitative (real-time) RT-PCR analysis in human colorectal carcinoma 
cells (Caco-2) and in healthy human colonic epithelial cells (HCEC).  
Accession Target 
Acronymous 
HCEC 
Cq mean (SD) 
Caco-2 
Cq mean (SD) 
Background 
Cq NTC (SD) 
NM_016083 CB1 33.12 (0.267)  VLE 30.86 (0.217) LE N/A (N/A) 
NM_001841 CB2 31.71 (0.136) CtB 29.89 (0.388) ME 36.50 (0.154) 
NM_007332 TRPA1 34.37 (0.259) VLE 32.29 (0.227) LE N/A (N/A) 
AF196175 TRPV1 28.05 (0.091) ME 25.86 (0.100) ME 35.88 (0.483) 
NM_016113 TRPV2 34.00 (0.500) VLE 30.19 (0.158) LE N/A (N/A) 
NM_024080 TRPM8 33.05 (0.519) CtB 30.06 (0.120) LE 36.88 (0.397) 
NM_000524 5HT1A 31.64 (0.180) CtB 29.25 (0.149) ME 35.90 (0.310) 
 
Cq, quantitative cycles; SD, standard deviation of quantitative cycles; NTC, negative 
control minus template; N/A, not applicable, no quantitative cycles detected within 40 
repeats. HE, high expression; ME middle expression; LE, low expression; VLE, very 
low expression; CtB, close to background. Quality significance parameters: ∆ (Cqmean-
Cqbkg) ≥  5;  replicate samples CqStddev ≤ 0.500. 
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Figure 44. Cannabigerol (CBG) reduces cell viability, evaluated by the MTT assay, in human colorectal 
cancer (Caco-2) cells in a time- and concentration-dependent manner. Caco-2 cells were incubated with 
increasing concentration of CBG (1-30 µM) for 3, 6, 12, 24 and 48 hours in a medium containing 1% 
FBS. Each bar represents the mean±SEM of three independent experiments. *p<0.05, **p<0.01 and 
***p<0.001 vs control (untreated cells). 
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Figure 45. Inhibitory effect of cannabigerol (CBG), evaluated by the MTT assay, on cell viability in 
human colorectal cancer (HCT 116) cells (A) and in healthy human colonic epithelial cells (HCEC) (B). 
Both cell lines were incubated with increasing concentration of CBG (1-30 µM, 24 h exposure) in a 
medium containing 1% FBS. Each bar represents the mean ±SEM of three independent experiments. 
***p<0.001 vs control (untreated cells). 
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Figure 46. Cytotoxic effect of cannabigerol (CBG, 10 µM in a 1% FBS medium, 24 h exposure), 
evaluated by the MTT assay, alone or in the presence of (A) AM251 (1 µM, selective CB1 receptor 
antagonist), AM630 (1 µM, selective CB2 receptor antagonist) and (B) ruthenium red (RR, 10 and 25 
µM, a non-selective TRP channels antagonist) in colorectal cancer (Caco-2) cells. The antagonists were 
incubated 30 min before CBG. Each bar represents the mean ± SEM of three independent experiments. 
#p<0.001vs control; *p<0.05 vs CBG alone. 
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Figure 47. Effect of AMTB (5-50 µM, A), cannabidiol (CBD, 1-30 µM, B), cannabidivarin (CBDV, 1-
30 µM, C) and cannabichromene (CBC, 1-30 µM, D) on cell viability, evaluated by the MTT assay, in 
colorectal cancer (Caco-2) cells. Cells were incubated with increasing concentration of compounds (24 
h exposure in a 1% FBS medium). Each bar represents the mean ± SEM of three independent 
experiments. **p<0.01 and ***p<0.001 vs control (untreated cells). 
 
 
control 1 3 10 30
0
25
50
75
100
125
******
cannabidiol (µM)
Ce
ll 
v
ia
bi
lit
y 
(%
)
control 1 3 10 30
0
25
50
75
100
125
***
CBC (µM)
Ce
ll 
v
ia
bi
lit
y 
(%
)
control 1 3 10 30
0
25
50
75
100
125
***
**
cannabidivarin (µM)
Ce
ll 
v
ia
bi
lit
y 
(%
)
control 5 10 25 50
0
25
50
75
100
125
***
**
AMTB (µM)
C
el
l v
ia
bi
lit
y 
(%
)
114 
 
A      B 
 
 
  
Figure 48. Cannabigerol (CBG) induces apoptosis in colorectal cancer (Caco-2) cells. (A) 
Morphological assessment of colorectal cancer (Caco-2 cells) evaluated by eosin-haematoxylin staining 
revealed the absence of death in untreated cells (upper pannel) and the presence of cells with a reduced 
size, showing an hypereosinophilic cytoplasm, hyperchromic nucleus, irregular nuclear membrane and 
nuclear material outside the nucleus in CBG-treated cells (10 µM, 24 h incubation in a 1% FBS, down 
pannel). Original magnification 200X. The figure is representative of 3 experiments. (B) Increase of 
caspase3/7 enzymatic activity evaluated by Caspase-Glo®3/7 assay. In the plot each point represents the 
mean of three independent determination (the mean standard error was not greater of 10% of the 
graphed value). In the insert panel a picture of part of the plate is shown. The cell amount in each dot 
increases from left to right as reported in the  plot abscissa. The increase of caspase 3/7 enzymatic 
activity (2.43 fold) was calculated by the ratio of the curve slopes: 239.0 and 98.41 for CBG and vehicle 
treated cells, respectively. 
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Figure 49. Effect of cannabigerol (CBG, 10µM in a 1% FBS medium, 24 h exposure) on reactive 
oxygen species production in colorectal carcinoma (Caco-2) cells (A) and healthy human colonic 
epithelia cells (B). Data represent mean ± SEM of 6 experiments. ***p<0.001 vs control. 
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5.0 DISCUSSION 
Inflammatory bowel disease (IBD) and colorectal cancer (CRC) are widespread diseases which 
affect millions of persons worldwide. Despite the progress in pharmacotherapy, preventive 
measures and cures are still unsatisfactory. Thus, there is an urgent need for safe and effective 
innovative therapeutics. During the PhD work, a number of non-psychotropic cannabinoids 
from Cannabis sativa have been evaluated in experimental models of IBD and colon cancer. 
These include CBD, CBG, CBC and THCV. Additionally, a botanical extract with high content 
of CBD (here named CBD BDS) has been evaluated in experimental models of colon cancer. 
The rationale for studying pCBs both in intestinal inflammation and colon cancer lies in the 
observation that clinical IBD represents an example of a condition that greatly increases the 
risk of CRC. 
5.1 Inflammatory bowel disease (IBD) 
Preparations of Cannabis have been used since antiquity as medicinal agents to alleviate the 
symptoms of inflammation, including IBD (Zurier, 2003). Recently, clinical  studies, by 
showing beneficial effects of Cannabis use in humans, seem to confirm such anecdotal reports 
(Naftali et al., 2011; Lahat et al., 2012; Lal et al., 2011; Naftali et al., 2013).The effect of ∆9-
THC and CBD, two main Cannabis constituents, on experimental models of IBD is well 
established and their effect on intestinal inflammation has been extensively reviewed 
(Alhouayek and Muccioli, 2012; Esposito et al., 2013). However, the issue of whether other 
Cannabis constituents contribute to the anti-inflammatory effect of the plant is a matter of 
investigation. In the present work we have investigated the anti-inflammatory effects of three 
non-psychotropic phytocannabinoids, namely CBG, CBC and THCV. 
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5.1.1 Effect of CBG, CBC and THCV on experimental colitis 
The potential anti-inflammatory effect of pCBs was verified by using the DNBS model of 
colitis. DNBS is dissolved in ethanol, which provokes the destruction of the mucosal barrier. 
DNBS evokes granulomas with infiltration of inflammatory cells in all layers of the intestine 
(Hibi et al., 2002).  
We have found that CBG, CBC and THCV reduced colon weight/colon length ratio of the 
inflamed colon, which is considered a reliable and sensitive indicator of the severity and extent 
of the inflammatory response (Gálvez et al., 2000). Because the main goal in IBD is to cure 
rather than to prevent, all the phytocannabinoids tested were given after the inflammatory 
insult. CBG and CBC were studied more thoroughly and for such compounds histological 
analysis, immunoistochemistry, neutrophil infiltration and intestinal membrane integrity studies 
were performed. Additionally, the effect of CBG was evaluated on cytokine levels and 
enzymes (COX-2 and iNOS) expression.  
Histological examination showed that CBG and CBC reduced the signs of colon injury; 
specifically, in the colon of phytocannabinoid-treated animals, the glands were regenerating, 
the oedema in sub-mucosa was reduced and the infiltration of granulocytes into the mucosa and 
sub-mucosa was reduced. The curative effect of both CBG and CBC was further supported by 
their capability to reduce or abrogate the increase in intestinal permeability induced by DNBS 
administration (notably, CBG restored completely the integrity of intestinal epithelium). 
Accordingly, neutrophil infiltration, revealed by measuring MPO activity (Krawisz et al., 
1984), was likewise reduced by both pCBs. Furthermore immunohistochemical analyses 
demonstrated that CBG and CBC limited the colonic diffusion of Ki-67, a useful marker for the 
evaluation of dysplasia in ulcerative colitis (Andersen et al., 1998). 
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As stated above, CBG was investigated more in details and, for this phytocannabinoid we 
performed further ex vivo studies in the colon of DNBS-treated mice. Specifically, we 
measured some cytokines which are known to be involved in IBD (Madsen, 2002) such as IL-
1β (a cytokine which plays an important pro-inflammatory role in the initiation and 
amplification of the intestinal inflammatory response) (Strober and Fuss, 2011), IL-10 (a 
regulatory cytokine which inhibits pro-inflammatory cytokine release, resulting in anti-
inflammatory effects within the gut) (Barbara et al., 2000) and IFN-γ, another pro-
inflammatory cytokine that  plays a crucial function in the initiation of experimental colitis 
(Strober and Fuss, 2011; Ito et al., 2006). Also, we measured iNOS and COX-2 expression, two 
key enzymes that play a pivotal role in gut inflammation (Kolios et al., 2004; Wallace and 
Devchand, 2005) and investigated the potential antioxidant effect of CBG. Consistent with 
previous studies, we observed that intracolonic administration of DNBS caused an increase in 
colonic IL-1β and interferon-γ as well as a decrease in IL-10 levels (Lamine et al., 2004; 
Borrelli et al., 2009). More importantly, we found that CBG counteracted the colonic variations 
of the three cytokines, thus suggesting the possible involvement of these cytokines in CBG-
mediated anti-inflammatory effects. We also demonstrated here that  the expression of both 
iNOS and COX-2 was increased in the colon of DNBS-treated mice and that CBG reduced the 
expression of the iNOS, but not COX-2 protein. Others have reported that CBG inhibits COX-2 
activity in intestinal cells, but in a higher concentration range,  and decreases prostaglandin 
production in the human colon adenocarcinoma (HT29) cell line (Ruhaak et al., 2011). Finally, 
CBG was able to restore SOD activity, suggesting its potential antioxidant effects in the 
inflamed gut.     
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5.1.2 Experiments in peritoneal macrophages 
In order to give some insights into the mode of action of the three pCBs, we investigated their 
effect on peritoneal macrophages. Macrophage targeting treatment ameliorates colonic 
inflammation in experimental colitis models and the regulation of abnormal responses of 
macrophages appears to be a promising therapeutic approach for the treatment of IBD (Yoshino 
et al., 2010). When activated by inflammatory stimuli (for example LPS), macrophages express 
iNOS and consequently produce a large amount of NO (Moncada et al., 1991). We thus 
evaluated the effect of the three pCBs on LPS-stimulated nitric oxide production in isolated 
peritoneal macrophages.  
We found  that CBG, CBC and THCV reduce the levels of nitrites, the stable metabolites of 
NO. The inhibitory effect of CBG and THCV on LPS-induced nitrite levels was associated to 
down-regulation of iNOS, suggesting that inhibition of induction of such enzyme is one of the 
mechanisms underlying the inhibition of NO production by the pCBs. Regarding CBC, it is 
unlikely that it affects the processes linked to the induction of iNOS since the 
phytocannabinoid: i) was pharmacologically active when given both 30 min before LPS as well 
as 15 h after the pro-inflammatory insult, i.e. once the enzyme had been already expressed and 
ii) did not affect iNOS mRNA and protein expression, as revealed by RT-PCR and western blot 
analyses. On the other hand, CBC reduced the levels of both IL-10 and IFN-γ, two cytokines 
which limit the inflammatory response in LPS-treated macrophages (Hawiger, 2001; Moore et 
al., 2001). The ability of macrophages to overproduce IL-10 (an anti-inflammatory cytokine) in 
response to LPS has been previously documented (Brightbill et al., 2000) and can be 
considered as an adaptive reaction of the macrophages aiming at counteracting the 
inflammatory insult. 
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In order to explore the molecular target of CBG, THCV and CBC action, we considered the 
possibility that such phytocannabinoids may affect the components of the so-called endogenous 
cannabinoid system. Specifically: i) CBG was shown to behave as a partial agonist of CB1 and 
CB2 receptors (Cascio et al., 2010), although exhibiting low affinity for these receptors 
(Pollastro et al., 2011), and to inhibit the reuptake of the endocannabinoid anandamide (De 
Petrocellis et al., 2011); ii) CBC inhibits endocannabinoid re-uptake, and thus to potentially 
activate indirectly – via increased extracellular endocannabinoid levels – the cannabinoid 
receptors (Ligresti et al., 2006; De Petrocellis et al., 2011); iii) THCV behaves as a CB1 
antagonist and a CB2 partial agonist (Pertwee, 2008).The possible involvement of cannabinoid 
receptors in CBG, CBC and THCV action was studied by evaluating: 1) the effect of selective 
CB1 and CB2 receptor antagonists on phytocannabinoids-induced inhibition of nitrite 
production, and 2) possible alterations in cannabinoid receptor mRNA produced by the 
phytocannabinoids in LPS-challenged macrophages. 
Our results suggest that cannabinoid receptor antagonists can modulate the pharmacological 
action of the three pCBs, although in a different way. Specifically: 
i) the inhibitory  effect of THCV on nitrite levels was counteracted by SR 144528 (CB2 
receptor antagonist), but not by rimonabant (CB1 receptor antagonist). Our data are 
consistent with the ability of this phytocannabinoid to activate CB2 receptors in binding 
studies and decrease carrageenan-induced oedema in mice in a CB2 receptor-sensitive 
way (Bolognini et al., 2010). This result is of relevance considering that CB2 receptors 
are up-regulated in inflammatory bowel conditions (Izzo, 2007) and CB2 agonists 
ameliorate experimental colitis (Storr et al., 2009). On the other hand, THCV reduced 
LPS-induced CB1 receptor hyper-expression, a relevant information in the light of the 
observation that CB1 receptor activation reduces nitrite production in LPS-challenged 
macrophages (Aviello et al., 2011) as well as ameliorates experimental colitis (Storr et 
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al., 2010). Importantly, among the phytocannabinoids tested, THCV was the unique to 
counteract the elevation in IL-1β and COX-2 induced by LPS, which is relevant 
because IL-1β represents one of the main pro-inflammatory cytokines able to induce 
COX-2 expression in macrophages (Samad et al., 2001; Liu et al., 2003). 
ii) The inhibitory effect of CBG on nitrite production was not modified by the CB1 
receptor antagonist rimonabant. By contrast, the CB2 receptor antagonist SR 144528, at 
a concentration which was per se inactive, further augmented the inhibitory effect of 
CBG on nitrite production, suggesting a modulatory role of CB2 receptors. In other 
words, our results suggest that an endogenous cannabinoid tone may exists, via CB2 
receptors, influencing negatively the anti-inflammatory effect of CBG signalling. 
Alternatively, it is  possible that CBG can merely synergize with SR 144528, by 
unmasking the anti-inflammatory action of a per se inactive dose of this antagonist. 
Moreover, we found that CBG did not modify the effect of LPS on CB1 and CB2 
receptor mRNA expression. 
iii) The inhibitory effect of CBC was further increased by a per se inactive concentration of  
rimonabant. These results, which are similar to those observed for the modulation of 
CBG action by a CB2 receptor antagonist described above, negate the possibility that 
CBC acts via CB1 direct or indirect activation. This hypothesis is also supported by the 
results we obtained in  the [35S]GTPγS binding assay performed with hCB1-CHO cell 
membranes. Thus, we found that CBC, at concentrations that included the one at which 
it significantly inhibits nitric oxide production (1 µM), did not induce any significant 
activation of  cannabinoid CB1 receptors. Moreover, using the same assay, we also 
found that when CBC was administered 30 min after 0.1µM rimonabant, it did not 
significantly affect the Emax of this compound for its inhibition of [35S]GTPγS binding. 
It might be possible that an endogenous CB1 tone exists, which may couple negatively 
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to the CBC signalling pathway and counteract CBC inhibition of nitrite production. 
Indeed, we found that LPS enhances anandamide levels in macrophages, and that CBC, 
instead, only elevates OEA levels. According to some Authors, also OEA, but not PEA 
(the levels of which were not elevated by CBC) is taken up by cells through the same 
mechanism responsible for anandamide uptake (Hillard et al., 1997; Alhouayek and 
Muccioli, 2012). It is possible that CBC could not elevate anandamide levels because 
these were already maximally up-regulated by LPS. OEA, which is chemically-related 
to anandamide, was previously shown to produce anti-inflammatory effects (Lo Verme 
et al., 2005) and hence, it is possible that a part of the beneficial effect of CBC 
observed here in macrophages could be due to its ability to increase OEA levels. 
Finally, we found that CBC did not affect LPS-induced changes in CB1 and CB2 
cannabinoid mRNA expression. These results rule against the possibility that this 
phytocannabinoid could exert anti-inflammatory actions in macrophages by altering 
cannabinoid mRNA receptor expression. 
5.1.3 Conclusions 
Our results show that the degree of intestinal inflammation caused by intracolonic 
administration of DNBS is substantially reduced by a curative treatment of mice with the 
Cannabis-derived ingredients CBG, CBC and THCV. More in depth ex vivo investigations on 
CBG showed that its anti-inflammatory  action was associated to modulation of cytokine (IL-
1β, IL-10 and interferon-γ) levels and down-regulation of iNOS  expression. 
Studies on peritoneal macrophages suggest that the three pCBs inhibited NO production, an 
effect associated to inhibition of iNOS expression (for CBG and THCV, but not for CBC). 
THCV was the unique among the phytocannabinoids to counteract the elevation in IL-1β and 
COX-2 induced by LPS. The effect of THCV, but not CBG or CBC, was mediated by CB2 
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receptor activation, since its effect was abrogated by a CB2 receptor antagonist. However, 
based on the observation that the CBC response on macrophages was augmented in the 
presence of CB1 antagonists and the CBG response was likewise increased in the presence of a 
CB2 antagonist, it is possible that an endogenous cannabinoid ‘‘tone’’ coupled at CB1 and CB2 
receptors influences negatively the anti-inflammatory effect of CBC and CBG signalling, 
respectively. 
5.2 Colorectal cancer (CRC) 
Colorectal cancer (CRC) is an important health problem across the world.  It is noteworthy that 
the CRC pathological process can develop spontaneously or can develop on the grounds of 
inflammatory bowel disease, thus suggesting a link between intestinal inflammation and 
cancer. Although significant progress has been made in understanding CRC development 
through epidemiological, laboratory and clinical studies, this type of cancer continues to be a 
major public health problem in the United States and many other parts of the world. 
Accordingly, novel therapeutic approaches, including chemopreventive measures, are urgently 
needed (Madka and Rao, 2013). Cannabis extracts and pCBs have demonstrated direct anti-
tumoural effects and are also used in cancer patients to stimulate appetite as well as antiemetics 
(Fowler et al., 2010; Carter et al., 2011; Pertwee, 2012; Velasco et al., 2012; Massi et al., 
2013). 
We have investigated here the intestinal anti-tumoural effects of CBG and CBG as well as of a 
Cannabis extract with high content in CBD, here named CBD BDS. Relevant for the present 
investigation are the observation that both CBD and CBG: i) displayanti-inflammatory effects 
in the gut  [Borrelli et al., 2009; Jamontt et al., 2010, (see also results reported above)], a 
pertinent observation in the light of the well-known association existing between intestinal 
inflammation and colorectal cancer (Terzić et al., 2010); ii) inhibit the metabolism  of 
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endocannabinoids (Izzo et al., 2009; De Petrocellis et al., 2011), which exert antitumoural 
effects in the gut (Izzo and Camilleri, 2009); iii) inhibit cell growth in a number of cell lines, 
including colorectal cancer cells (Ligresti et al., 2006). Furthermore ,CBD BDS is one of the 
main components of Sativex (Nabiximols in the USA), a cannabinoid formulation which has 
been shown to provide a protection against chemotherapy-induced nausea and vomiting (Duran 
et al., 2010) and has been proposed as a useful add-on analgesic for patients with opioid-
refractory cancer pain (Johnson et al., 2010; Portenoy et al., 2012; Johnson et al., 2013). In this 
work, we have demonstrated that CBD, CBD BDS and CBG exerted protective effects in 
experimental models of colon carcinogenesis. 
5.2.1 Effect of CBD, CBD BDS and CBG on experimental colon carcinogenesis in vivo 
We have evaluated the effect of the pCBs in two experimental models of colon cancer, i.e., the 
AOM model, which is useful for the study of chemopreventive substances and the xenograft 
model, which is more appropriate for the evaluation of curative effects. AOM is a potent 
carcinogen causing a high incidence of colon cancer in rodents and its development closely 
mirrors the pattern seen in humans. The AOM colon cancer model is extensively used in the 
study of the underlying mechanisms of human sporadic colon cancer (Chen and Huang, 2009). 
The xenograft  model of colon cancer used in the present work is generated by the implantation 
of colorectal cancer cells into nude mice. 
We have shown here that CBD, CBD BDS and CBG exerted beneficial effects in AOM-treated 
mice. More specifically, we found that: i) CBD, at the dose of 1 mg/kg, exerted an optimal 
chemopreventive effect, being able to significantly reduce ACF, polyps and tumours. At the 
highest 5 mg/kg dose, it prevented the formation of polyps only; ii) CBD BDS (5 mg/kg) 
significantly reduced the formation of ACF and polyps; tumours formation was reduced by 
40%, although a statistical significance was not achieved; iii) CBG, at the 5 mg/kg dose, 
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completely abrogated the formation of ACF and reduced by one half the number of tumours 
induced by AOM in mice. Furthermore, daily injection with pCBs resulted in a reduction of the 
tumour growth in the xenograft model of colon cancer. Collectively, such results highlight the 
potential chemopreventive and curative effect of the investigated pCBs. 
CBD was evaluated more in depth. For this cannabinoid, we evaluated the ex vivo intestinal 
biochemical changes (i.e. caspase-3, phospho-Akt, iNOS, COX-2 evaluations) associated to its 
chemopreventive effect. We found that the protective effect of CBD on colon carcinogenesis 
was associated to up-regulation of the active fragment of caspase-3, i.e. one of the major final 
effectors of the apoptotic process (Kim, 2005). Proapoptotic mechanisms induced by CBD have 
been previously documented in human breast carcinoma and glioma cells (Ligresti et al., 2006; 
Massi et al., 2006).When we investigated the potential role of the phosphoinositide3-kinase 
(PI3K)/Akt pathway, which is crucial for the regulation of cell growth, migration, 
differentiation, and apoptosis (Sheng et al., 2003; Wang et al., 2001), we found that CBD 
counteracted AOM-induced up-regulation of the phosphorylated form of Akt protein. These 
data are suggestive of an involvement of the PI3K-Akt survival signalling cascade in CBD-
induced protective effect. Interestingly, Greenhough and colleagues found that the psychotropic 
cannabinoid ∆9-THC, via CB1 activation, induced apoptosis in colorectal cancer cells and that 
its protective effect also involved inhibition of the PI3K-Akt survival signaling cascade. 
Finally, we found that CBD did not change the overexpression of COX-2 and iNOS, two key 
enzymes involved in colon carcinogenesis (Rao, 2004; Wu et al., 2010). Likewise, the 
protective effect of CBD against glioma in vivo was not associated with changes in COX-2 
activity in glioma tumour tissues (Kim, 2005). We have previously shown that the anti-
inflammatory effect of CBD in the gut is associated with down-regulation ofiNOS, but not 
COX-2, expression (Borrelli et al., 2009). 
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5.2.2 Effect of CBD, CBD BDS and CBG on colorectal cancer cell growth 
In order to give further insights into the antitumoural actions observed in vivo, we investigated 
the effect of these phytocannabinoids on several colorectal carcinoma cell lines.  
Cannabidiol (CBD) 
CBD is known to exert antiproliferative effects in different tumour cell lines (Massi et al., 
2006; Ligresti et al., 2006). In the present thesis, we have shown that this compound, at not-
cytotoxic concentrations, exerts antiproliferative effects in three different colorectal carcinoma 
cell lines, i.e. Caco-2, HCT116 and DLD-1 cells. To evaluate the target(s) downstream the in 
vitro effect of CBD, we investigated, in Caco-2 cells, the potential involvement of: (1) 
cannabinoid receptors, because CBD may increase endocannabinoid levels (De Petrocellis et 
al., 2011; Izzo and Camilleri, 2009), which, in turn, may exert antiproliferative effects in vitro 
via cannabinoid receptor activation (Ligresti et al., 2003); (2) TRPV1, because CBD may 
directly activate this ion channel; in addition, anandamide, an endogenous TRPV1 ligand (De 
Petrocellis et al., 2011), is elevated in the AOM model of colon cancer (Izzo et al., 2008), as 
well as in biopsies of patients with colon cancer (Ligresti et al., 2003); (3) PPARγ, because 
cannabidiol may activate PPARγ and PPARγ agonists exert protective effect in colon 
carcinogenesis (O’Sullivan et al., 2009). Our data show that the antiproliferative effect of CBD 
was counteracted by rimonabant and AM251 (two CB1 receptor antagonists), capsazepine (a 
TRPV1 receptor antagonist) and GW9662 (a PPARγ receptor antagonist), thus suggesting that 
this non-psychotropic phytocannabinoid may exert anti-cancer effects in vitro through multiple 
mechanisms. In line with our results, it has been demonstrated that CBD reduces intestinal 
permeability in Caco-2 cells in a CB1 and TRPV1 antagonist-sensitive manner (Alhamoruni et 
al., 2010). Because CBD does not bind CB1 receptors with high affinity, the reversal by the 
CB1 antagonists could be explained by indirect activation of such receptors, e.g. via 
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enhancement of endocannabinoid(s) in colorectal carcinoma cell lines. In support of this 
hypothesis, CBD increased 2-AG levels in Caco-2 cells. In addition, anandamide levels 
appeared to be increased with this concentration of CBD although in a non-statistically 
significant manner. Although FAAH is not the primary enzyme involved in 2-AG metabolism 
(Di Marzo, 2008), it has been previously demonstrated, in both Caco-2cells and colon of AOM-
treated mice (Izzo et al., 2008; Izzo and Camilleri, 2009), that arachidonoyl-serotonin, another 
FAAH inhibitor, increases the content of both anandamide and 2-AG. 
Finally, using the single cell electrophoretic assay (Comet assay), a widely accepted tool for 
investigating DNA damage, we have demonstrated that CBD was unable to induce DNA 
damage and, more importantly, whereas it exerted protective effects against hydrogen peroxide 
induced DNA damage. These results are of interest because DNA mutation is a crucial step in 
carcinogenesis and oxidatively derived DNA lesions have been observed in many tumours, 
where they are strongly implicated in the etiology of colon cancer. 
Cannabidiol botanical drug substance (CBD BDS) 
CBD BDS is one of the main components of Sativex (Nabiximols in the USA), a cannabinoid 
formulation actually used for the treatment of pain and spasticity associated with multiple 
sclerosis. CBD BDS is a mixture containing many pCBs (mainly CBD) together with other 
pCBs, such as  THC (see Figure 5). Because CBD, the main component of CBD BDS, exerts 
antiproliferative actions in colorectal cancer cells (see results discussed above), we compared 
the antiproliferative effect of CBD BDS and pure CBD in colorectal cancer cells, such as DLD-
1 and HCT116 cells. As expected, both pure CBD and CBD BDS exerted antiproliferative 
effects. Importantly, the effect of both CBD BDS and CBD was selective for tumoural cells, as 
the phytocannabinoid and the Cannabis extract did not show antiproliferative effects in healthy 
human epithelial cells. In contrast to other assays (Comelli et al., 2008; Capasso et al., 2011), 
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there was no significant difference in potency and efficacy between CBD BDS and pure CBD. 
In agreement with the results obtained in Caco-2 cells (see above), we found that the 
antiproliferative effect of CBD in DLD-1 cells was counteracted by selective cannabinoid CB1 
- but not CB2 - receptor antagonists, suggesting an involvement of CB1 receptors via 
enhancement of endocannabinoids levels. When we evaluated the pharmacological effect of 
CBD BDS, we found that its action on cell proliferation was sensitive to both CB1 and CB2 
receptor antagonists, thus suggesting that CBD and CBD BDS have a different mode of action. 
In order to give insights into the observed different mode of action, we compared the 
cannabinoid receptor binding of CBD BDS to that of pure CBD. In hCB1and hCB2 transfected 
CHO cells, we found that CBD BDS showed greater affinity than pure CBD for both CB1 and 
CB2 receptors. Pure CBD had little affinity for either CB1 or CB2 receptors, with only the 
concentration of 10 µM exhibiting any significant binding. Among the other pCBs contained in 
CBD BDS (see Figure 5 and Table 1), THC has been shown to be a potent CB1 and CB2 
receptor agonist, CBN has a weak partial agonist activity at the CB1 receptor and moderate 
partial agonist activity at the CB2 receptor and CBG has been shown to be a  weak ligand at 
both CB1 or CB2 receptors (Pertwee, 2005; Pertwee, 2008; Cascio et al., 2010; Pollastro et al., 
2011). Together, these binding data suggest that the presence of both THC (contained in CBD 
BDS at a 2.4% concentration) and to a very less extent CBN (present in CBD BDS at a 0.1% 
concentration) could account for the ability of CBD BDS to displace [3H]CP55940 with higher 
affinity than pure CBD. It is also noteworthy that CBD BDS most probably shares the ability of 
CBD to activate cannabinoid receptors indirectly by increasing the levels of endogenously 
released endocannabinoids, as showed above. 
 
 
129 
 
Cannabigerol (CBG) 
To investigate the effect of CBG on colorectal cancer cell growth, we adopted a different 
approach, i.e. we compared the effect of this phytocannabinoid on cell growth on tumoural vs 
healthy cells. Experiments were performed in the presence of low serum concentrations, 
because there is evidence in the literature that the effect of phytocannabinoids on tumoural cells 
viability is increased with a low serum proteins concentration (De Petrocellis et al., 2013). We 
found that CBG reduced viability in two colorectal carcinoma cell lines. Importantly, the effect 
of CBG was rather selective for colorectal carcinoma cells, showing that the phytocannabinoid 
has a very low inhibitory action on healthy human colonic epithelial cells. In order to 
investigate the mode of CBG action, we considered a number of  receptors  (i.e. cannabinoid 
receptors, TRPA1, TRPV1 and TRPV2  channels, and 5HT1A receptors) which have been 
shown, based on pharmacodynamic studies, to be targeted by CBG. It is well established that 
CB1 or CB2 receptor activation results in inhibition of colorectal cell growth (Ligresti et al., 
2003; Izzo and Coutts, 2005; Izzo and Camilleri, 2009). CBG has been shown to behave as a 
weak partial agonist of CB1 and CB2  receptors (Cascio et al., 2010). Furthermore, CBG 
inhibits the reuptake of endocannabinoids, which have been detected in Caco-2 cells (as 
reported above) and thus might indirectly activate – via increased extracellular 
endocannabinoid levels – the cannabinoid receptors. We have here observed that the inhibitory 
effect of CBG on cell viability was unaffected by the selective CB1 receptor antagonist AM251 
and further increased by the CB2 receptor antagonist AM630. Such results negate the 
possibility that CBG acts via direct or indirect activation of cannabinoid receptors and rather 
suggest that an endogenous CB2 tone exists, which may couple negatively to the CBG 
signalling pathway leading to the inhibition of cell viability. A similar result has been observed 
also in peritoneal macrophages (as discussed above), where the inhibitory effect of CBG on 
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LPS-stimulated nitrite production was further augmented by SR 144528, another CB2 receptor 
antagonist.  
TRP channels form a superfamily of  proteins which affect several pathological processes, 
including the fate of cancer cells (Shapovalov et al., 2001; Gkika and Prevarskaya, 2009; 
Santoni et al., 2011). CBG has been shown to behave as a relatively potent and highly effective 
TRPA1 agonist and a weak agonist at TRPV1 and TRPV2 channels (De Petrocellis et al., 2011; 
De Petrocellis et al., 2012). However, it is unlikely that CBG acts via activation of TRPA1 
and/or TRPV2 channels since ruthenium red, a non-selective TRP channel antagonist, at  
concentrations which were several fold higher than the IC50 able to block TRPA1/TRPV1-2 
channels, did not modify the effect of CBG on cell viability. It has been reported than CBG is 
an antagonist of TRPM8 (De Petrocellis et al., 2011), which is involved in the regulation of cell 
proliferation/apoptosis (Prevarskaya et al., 2007) and it is now considered as a promising target 
for cancer, particularly for prostate cancer. TRPM8 mRNA has been detected in a number of 
primary tumours, including colorectal cancer tissues (Tsavaler et al., 2001). Our results showed 
that TRPM8 mRNA was expressed in colorectal cancer cells and, more importantly, that the 
effect of CBG on cell viability was mimicked by the synthetic TRPM8 antagonist AMTB, by 
cannabidiol and cannabidivarin (two phytocannabinoids which share the ability of CBG to 
block the TRPM8). By contrast, cannabichromene, a  phytocannabinoid which does not block 
the TRPM8 (De Petrocellis et al., 2011) had a negligible effect on colorectal cell viability. 
Additionally, CBG exerted a very weak cytotoxic effect in healthy human colonic epithelial  
cells, in which TRPM8 mRNA is faintly expressed. Collectively, such results suggest that 
TRPM8 might be involved in CBG-induced inhibition of colorectal cancer cell growth. Finally, 
it is very  unlikely that the effect of CBG is due to the block of 5-HT1A, a receptor involved in 
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carcinogenesis (Dizeyi et al., 2004), since CBG effect was not mimicked by a well-established 
selective 5-HT1A antagonist. 
Apoptosis and necrosis are the two major processes leading to cell death (Maghsoudi et al., 
2012). Previous investigators have shown that endogenous and plant cannabinoids can induce 
apoptosis in cancer cells (Galve-Roperh et al., 2000; Jacobsson et al., 2001). However, to date, 
no information for CBG exists. By using eosin-haematoxylin staining, we have shown that the 
inhibitory effect of CBG on cell growth was due to apoptosis induction rather than necrosis, a 
result which was confirmed by an enzymatic assay showing an increased activity of caspase 3 
and 7,  two cysteine proteases specifically involved in apoptosis (Kumar, 2009), in CBG treated 
cells. Finally, we investigated the possible involvement of ROS in CBG-induced inhibition of 
tumoural cell growth. ROS are highly reactive molecules, generally derived from the normal 
metabolism of oxygen,  that are produced primarily in mitochondria. Although basal ROS 
levels are considered to be  physiological regulators of  cell proliferation and differentiation, in 
balance with biochemical antioxidants, high levels of ROS triggers a series of mitochondria-
associated events leading to  apoptosis (Li et al., 2012; Matés et al., 2012). The relationship 
between ROS and cancer has been also emphasized by the observation that many 
chemopreventive agents may be selectively toxic to tumor cells because they increase oxidant 
stress and enhance ROS generation, which in turn, causes apoptosis of cancer cells (Lee et al., 
2013). In the present study, we have shown that CBG, at the same concentration able to exert 
pro-apoptotic effects, selectively increased ROS production in colorectal cancer cells but not in 
healthy colonic cells, thus suggesting that ROS overproduction might be implicated in CBG-
induced apoptosis.  
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5.2.3 Conclusions 
Our data show that CBD, CBD BDS and CBG hinders the development and the  growth of 
colon carcinogenesis in vivo, by exerting both chemopreventive (in the AOM model of colon 
cancer) and curative (vs tumours generated by xenograft injection of colorectal cancer cells) 
effects. Data  on colorectal cancer cells suggest that CBD, CBD BDS and CBG inhibit cell 
growth in tumoural - but not in healthy - intestinal cells. CBD BDS and CBD exerted 
cannabinoid-mediated antiproliferative effects, with CBD being able to increase 
endocannabinoids levels. More in depth studies on CBD revealed that this phytocannabinoid 
protected DNA damage caused by an oxidative insult and exerted antiproliferative effects 
through multiple mechanisms, including involvement of CB1 receptors, TRPV1 and PPAR-γ. 
CBG also inhibited the growth of colorectal cancer cells, but with a  mechanism not involving 
activation of cannabinoid receptors, although CBG effect was further increased by a CB2 
receptor antagonist. CBG acted via a pro-apoptotic mechanism, and its effect on tumoural cell 
growth was associated to overproduction of ROS. Notably, the inhibitory effect of CBG on cell 
growth was  mimicked by other TRPM8 antagonists, thus suggesting that such receptor might 
be, at least in part, involved in its actions 
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6.0 Conclusions  
There is anecdotal evidence for the therapeutic benefit of Cannabis in a variety of human 
gastrointestinal disease conditions, that spans over many centuries. For example, some IBD 
patients anecdotally report that they experience relief by smoking marijuana. Additionally, 
Cannabis and isolated cannabinoids have been used in cancer patients to stimulate appetite and 
as antiemetics. Phytocannabinoids include about 100 phytocannabinoids, accumulated in tiny 
epidermal resinous glands of the Cannabis plant and characterized, in most instances, by 
specific and potent pharmacological activities. However,  most of the cannabinoids in Cannabis 
sativa have not been fully evaluated for their pharmacological activity. The results reported in 
this work supports the notion that the Cannabis plant is a treasure trove of potentially novel 
therapeutic agents for gastrointestinal diseases, including IBD and colon cancer. Briefly, we 
have shown that: 
1. The non-psychotropic Cannabis ingredient CBG, CBC and THCV  exert protective 
effects in a murine experimental model of IBD. In peritoneal macrophages  the three 
phytocannabinoids inhibited NO production, an effect associated to inhibition of iNOS 
expression  for  CBG and THCV (but not for CBC). Studies aiming at investigating the mode 
of action of the phytocannabinoids revealed that the effect of THCV involves direct activation 
of CB2 receptors. By contrast,  an endogenous cannabinoid ‘‘tone’’ at CB1  and CB2 receptors 
is likely coupled negatively to CBC and CBG anti-inflammatory actions, respectively. 
2. CBD, CBD BDS (a Cannabis extract with high content in CBD) and CBG exert 
chemopreventive curative effects in experimental models of colon cancer. Importantly, the 
phytocannabinoids/extract under investigation inhibited cell growth in tumoural - but not in 
healthy intestinal - cells. CBD BDS and CBD exerted cannabinoid-mediated antiproliferative 
effects via cannabinoid-mediated mechanisms, with TRPV1 and PPAR-γ possibly involved in 
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the antiproliferative action of CBD. By contrast, CBG inhibited the growth of colorectal cancer 
cells, but with a  mechanism not involving activation of cannabinoid receptors, although CBG 
effect, similarly to the action on macrophages, was negatively modulated by cannabinoid CB2 
receptors.  Notably, the inhibitory effect of CBG on cell growth was  mimicked by other 
TRPM8 antagonists, thus suggesting that such receptor might be, at least in part, involved in its 
actions. 
On the whole, these results could provide a pharmacological basis to explain, at least in part, 
the beneficial effects of Cannabis preparations observed in IBD and possibly in cancer patients. 
In a therapeutic prospective, the use of non-psychoactive plant cannabinoids appears to be a  
promising approach because their use is not associated to the unwanted side effects derived 
from activation of brain CB1 receptors. In the light of their safety records, it is believed that the 
non-psychotropic phytocannabinoids evaluated in this work  might be considered as  good 
candidates to be clinically evaluated for the prevention and/or treatment of  IBD and colon 
cancer. 
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